US20220331385A1 - Anti-cancer oncolytic virus combination therapies and elite responder selection platforms - Google Patents
Anti-cancer oncolytic virus combination therapies and elite responder selection platforms Download PDFInfo
- Publication number
- US20220331385A1 US20220331385A1 US17/660,051 US202217660051A US2022331385A1 US 20220331385 A1 US20220331385 A1 US 20220331385A1 US 202217660051 A US202217660051 A US 202217660051A US 2022331385 A1 US2022331385 A1 US 2022331385A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- subject
- oncolytic
- gut microbiota
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 244000309459 oncolytic virus Species 0.000 title claims abstract description 106
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 27
- 238000002648 combination therapy Methods 0.000 title description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 152
- 201000011510 cancer Diseases 0.000 claims abstract description 75
- 244000005709 gut microbiome Species 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 46
- 241000700605 Viruses Species 0.000 claims abstract description 24
- 230000006023 anti-tumor response Effects 0.000 claims abstract description 15
- 210000000987 immune system Anatomy 0.000 claims abstract description 14
- 230000000174 oncolytic effect Effects 0.000 claims abstract description 11
- 201000001441 melanoma Diseases 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 24
- 241000700635 Orf virus Species 0.000 claims description 22
- 208000020816 lung neoplasm Diseases 0.000 claims description 19
- 241000186000 Bifidobacterium Species 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 230000003190 augmentative effect Effects 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 8
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 31
- 238000007417 hierarchical cluster analysis Methods 0.000 abstract description 4
- 241000736262 Microbiota Species 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 88
- 241001465754 Metazoa Species 0.000 description 52
- 238000002347 injection Methods 0.000 description 48
- 239000007924 injection Substances 0.000 description 48
- 238000012360 testing method Methods 0.000 description 44
- 230000000259 anti-tumor effect Effects 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 27
- 210000001035 gastrointestinal tract Anatomy 0.000 description 26
- 239000002953 phosphate buffered saline Substances 0.000 description 26
- 230000001580 bacterial effect Effects 0.000 description 24
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
- 230000003612 virological effect Effects 0.000 description 20
- 238000012163 sequencing technique Methods 0.000 description 19
- 241001529936 Murinae Species 0.000 description 18
- 108020004465 16S ribosomal RNA Proteins 0.000 description 17
- 230000037396 body weight Effects 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 230000000813 microbial effect Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 241000894007 species Species 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000006143 cell culture medium Substances 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 230000003442 weekly effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 9
- 230000002601 intratumoral effect Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 239000012588 trypsin Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 6
- 235000010633 broth Nutrition 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000013401 experimental design Methods 0.000 description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 6
- 208000037841 lung tumor Diseases 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 206010061309 Neoplasm progression Diseases 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000009897 systematic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000005751 tumor progression Effects 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 244000005702 human microbiome Species 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241001430332 Bifidobacteriaceae Species 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 206010011906 Death Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012301 transgenic model Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000486634 Bena Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037438 passenger mutation Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000017610 release of virus from host Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- the present disclosure provides methods for administering to a subject gut microbiota and oncolytic viruses. Combinations of the viruses and gut microbiota and uses thereof for treating and preventing cancer are also provided.
- Cancer consists of a group of diseases marked by uncontrolled growth of malignant cells. There are over one hundred cancers that affect a large segment of the human population and account for about 13% of all fatalities. Cancer was responsible for over 8.2 million deaths worldwide in 2012, and this number is predicted to jump to 13 million by 2030. The number of new cancer cases diagnosed in 2012 worldwide was 14.1 million, and 58% of new cancer cases are found in developed countries like the US. Among children ages 0 to 14, an estimated 163,300 new cases were diagnosed in 2012, of which about 80,000 resulted in death (WHO, World Health Report 2014; National Center for Health Statistics, 2014; ACS. Global Cancer Facts & Figures, 2015).
- Checkpoint inhibitor therapy acts by modulating the host systemic immune response (La-Beck, Pharmacotherapy 35(10): 963-76, 2015; Rubin, Clin J Oncol Nurs. 19(6):709-17, 2015; Sharma & Allison, Science 348(6230): 56-61, 2015).
- mice fed with antibodies showed a significant decease in the activation of both CD4 + T effector cells and CD8 + tumor infiltrating lymphocytes (TIL), which play a critical role in the adaptive immune response during antibody-initiated tumor killing.
- TIL tumor infiltrating lymphocytes
- Oncolytic viruses are therapeutically used microbes (either naturally occurring or genetically-engineered) that preferentially infect and replicate in cancer cells in order to eliminate malignant tumors while avoiding toxicity (Seymour & Fisher, Br. J Cancer 114(4): 357-61, 2016; Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015; Turnbull et al., Viruses 7(12): 6291-312, 2015; Larissa et al., Trends Cancer 1(4): 266-77, 2015).
- OV Oncolytic viruses
- Oncolytic viruses target tumor cells precisely because the same genetic alterations that allow malignant tumor cells to proliferate and survive also promote the growth of lytic viruses (Hanahan & Weinberg, Cell 144(5): 646-74, 2011; Miest & Cattaneo, Nat. Rev. Microbiol. 12(1): 23-34, 2014; Burke et al., Curr. Opin. Virol. 13: 55-60, 2015). Additionally, drug-resistant cancer cells and cancer stem cells retain their susceptibility to OV, which are effective in the hypoxic environments characteristic of solid tumors (Shen & Hermiston, Gene Ther. 12, 902-10, 20051.
- Infected OV have the ability to coordinate cancer cell death at a suitable time point within the virus life cycle, which leads to the release of infectious viral particles (Seymour & Fisher, Br. J. Cancer 114(4): 357-61, 2016).
- OV-initiated tumor cell death not only raises the active intratumoral viral dose that infects more tumor cells, but also releases significant amounts of tumor-specific neoantigens that can be presented by intratumoral antigen presenting cells (APCs), such as activated DCs.
- APCs intratumoral antigen presenting cells
- These cells ignite a host systemic antitumor immune response, a second mechanism of cancer cell killing beyond the direct in situ viral lysis of the tumor (Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2014). This second mechanism is important for an effective antitumor response, as it will also kill metastatic cancer cells at distant sites previously unseen by the virus as well as intratumoral bystanders localized outside
- T-Vec clinical trials which gave statistically significant improved durable responses and heightened survival rates in patients with unresectable melanoma, expediting FDA approval of the first OV drugs (Andtbacka et al., J. Clin. Oncol. 33.25: 2780-00, 2015) While the best OV T-Vec trial showed promising results, there are still a host of problems that need to be addressed.
- 436 Phase III trials only a 16.3% durable response rate and a 26.4% objective response rate were observed, with only 10.9% of the participants achieving a complete response (Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015).
- OV has been used in more than 40 clinical trials to treat a spectrum of human malignancies, and one particular therapy has been successfully translated into the first FDA-approved OV drug (Harrington et al., Expert Rev. Anticancer Ther. 15(12): 1389-403, 2015).
- the efficacy and responsiveness rates across all OV trials remain disappointingly low, especially when factored into the overall survival rate (Buijs et al., Hum. Vaccin. Immunother. 11(7): 1573-84, 2015; Burke et al., Curr. Opin. Virol. 13: 55-60, 2015; Harrington et al., Expert Rev Anticancer Ther. 15(12): 1389-403, 2015; Kaufman et al., Nat.
- gut bacteria have been used as a nutraceutics, such as the probiotic in fermented food containing the Bifidobacterium genus within the Gram-positive actinobacteria phylum (Hill et al., Nat. Rev. Gastroenterol. Hepatol. 11: 506-14, 2014). It has also been used in routing clinical surgery though fecal microbiota transplantation (FMT) (NICE Interventional Procedure Guidance: 485, 2014). The composition of gut microbiota is regulated by the host's adaptive immune system component secretory immunoglobulins A (sIgAs) (Fransen et al., Immunity 43(3): 527-40, 2015).
- SIgAs adaptive immune system component secretory immunoglobulins A
- HMP Human Microbiome Project
- IHMC International Human Microbiome Consortium
- the understanding of the composition and functions of the human gut microbiota has increased dramatically in the post-metagenomic era (Segata et al., Genome Biol. 13:R42, 2012; Segata et al., Nat. Methods, 9(8): 811-14, 2012).
- There are about 100 trillion bacterial cells in the human gut and they can be categorized into five major phyla, of which approximately 160 species live in the large intestine of any individual (Rajilic-Stojanovic et al., FEMS Microbiol. Rev. 38: 996-1047, 2014; Segata et al., Genome Biol. 13:R42, 2012).
- a key aspect of the present invention is to employ commensal gut bacteria to pre-condition a subject's immune system to the anticancer activity of OV therapy.
- Provided herein are methods and combination therapies using gut microbiota to augment the anticancer potential of OV therapy.
- this invention can address the boosts that are necessary for the durable response and complete response rates.
- the present disclosure provides therapeutic methods for treating and preventing cancer by augmenting systematic treatments through certain commensal gut bacterial genera, including, but not limited to Bifidobacterium and Bacteroides , which can potentially boost systemic immune response within the host. These species exhibit significant anti-tumor synergies with checkpoint inhibitors CTLA-4, PD-1/or PDL-1 antibodies when tested in melanoma and colon cancer models or analyzed using melanoma patient samples.
- Checkpoint inhibitor therapies work by modulating the systemic immune response, one of the two mechanisms underlying OV-based therapies.
- This invention provides novel methods and combination therapies using OV and commensal gut bacteria species, whose composition in a patient's gut can be further modulated by herb medicine or extracts.
- This invention also provides methods for building elite responder selection platforms through hierarchical clustering analysis of genomic profiles for human gut microbiome.
- This invention is applicable to other live therapies (e.g. somatic cell and stem cell therapies), where efficacy relies on systemic activation of the host immune system.
- the present disclosure provides a method of treating and/or preventing cancer comprising administering to a subject an effective amount of gut microbiota, and administering to the subject an effective amount of an oncolytic virus having anticancer activity and that selectively targets tumor cells, wherein the gut microbiota pre-conditions the subject's immune system to antitumor responses and augments the anticancer activity of the oncolytic virus.
- the oncolytic virus is a virus within the poxviridae family.
- the oncolytic virus may be, but is not limited to, an orf virus, bovine popular stomatitis virus, pseudocopox virus, or vaccinia virus.
- the gut microbiota is the genus Bifidobacterium.
- the cancer is a type of cancer having a high degree of de novo mutations.
- the cancer is melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, or renal cancer.
- the oncolytic virus is administered to a subject from about one week to two months alter the gut microbiota is administered. Preferably, the oncolytic virus is administered about one month after the gut microbiota is administered.
- the subject is an animal. Animals can be non-human animals, mammal, or can include humans.
- gut microbiota is administered to human subjects at an effective amount of about 10 9 to 10 11 cfu.
- the OV may be administered to human subjects at an effective amount from about 10 5 to 10 10 pfu.
- the methods and kits provided herein rely on a pre-condition created by the gut microbiota to enhance the anticancer activity of the oncolytic virus.
- the anticancer activity of the OV is synergistically enhanced by the gut microbiota.
- the critical pre-condition for an effective antitumor response is an enhanced immune response, which may be achieved through commensal gut microbiota augmentation, one of the key concepts of this current invention.
- a platform is used to identify potential elite responders to the cancer treatment based on an abundance of the subject's particular gut microbiota.
- the platform is built through hierarchical clustering analysis of genomic profiles of the human gut microbiome.
- the platform identifies gut microbiota that suppress tumor progression.
- the pre-screened subject is predicted to respond favorably to an oncolytic virus based on the abundance of the subject's particular gut microbiota.
- combination therapies using gut microbiota and OV therapies are packaged as a kit.
- the packaged kit may contain instructions for administration and other reagents for administration.
- a kit is provided for the treatment of cancer, comprising a pharmaceutical composition comprising gut microbiota that pre-condition a subject's immune system to antitumor responses, a pharmaceutical composition comprising an oncolytic virus having anticancer activity and that selectively targets tumor cells, instructions for sequentially administering the gut microbiota and oncolytic virus, and wherein the gut microbiota augments the anticancer activity of the oncolytic virus.
- the kit is used where the cancer is a type of cancer having a high degree of de novo mutations.
- the cancer may be melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, or renal cancer.
- the kit may also comprise the gut microbiota, Bifidobacterium.
- FIG. 1 shows that tumor growth is influenced by the ablation of gut microbes.
- FIG. 2 shows a heatmap of 16S rRNA gene sequencing.
- FIG. 3 shows tumor growth curves for mice without antibiotic treatment.
- FIGS. 4A-C show that oncolytic viruses had no toxicity to the host.
- FIG. 5 shows no significant differences in mean body weights among study groups in the evaluation of the anti-tumor activity of OV/GM combination in a murine melanoma tumor model.
- FIG. 6 shows the synergistic anti-tumor activity of an OV/GM (POV-801+PGM-001) combination in a syngeneic murine melanoma tumor model.
- FIG. 7 shows the synergistic anti-tumor activity of OV/GM (POV-6014 PGM-001) combination in a syngeneic murine melanoma tumor model.
- FIG. 8 shows the synergistic anti-tumor effects of various OV/GM combinations in a syngeneic murine melanoma tumor model.
- FIG. 9 shows no significant differences in mean body weights among study groups in the evaluation of the anti-tumor activity of OV/GM combination in a murine lung tumor model.
- FIG. 10 shows no significant differences in mean spleen weights among study groups in the evaluation of the anti-tumor activity of OV/GM combination in a murine lung tumor model.
- FIG. 11 shows the synergistic anti-tumor activity of OV/GM (POV-601+PGM-001) combination in a murine lung tumor model.
- OVs oncolytic viruses
- the combination therapy comprises the orf virus (ORFV) due to its documented safety profile as well as its unique ability to cause repeat infections.
- ORFV exhibits an ability to induce robust stimulatory immune responses with the special involvement of natural killer (NK) cells and dendritic cells (DCs), and ORFV's replicative “niche” has an extensive vasculature, similar to a tumor microenvironment, which has beneficial effects on its anti-tumor activity (Rintoul et al., Mol. Ther. 20(6): 1148-57, 2012; Rziha et al., Methods Mol. Biol. 2016; 1349:177-200, 2016).
- NK natural killer
- DCs dendritic cells
- ORFV shows superior in vivo anti-tumor activities in immunocompetent murine lung cancer models and in human lung cancer xenograft models.
- ORFV recombinants containing either reporter or anti-tumor enhancing genes are designed to facilitate ORFV tissue distribution and biopsy analysis and boost ORFV's antitumor activity.
- ORFV is the main component of a combination antitumor treatment containing an augmenting agent.
- in vivo ORFV monitoring is carried out by a recently developed technology (Rziha et al., Methods Mol. Biol. 2016; 1349:177-200, 2016) that rapidly detects ORFV viral load and the delayed re-emergence of its genomes in the blood. Positive readout at an extended time point after ORFV administration indicates intratumoral viral replication and subsequent leakage into the systemic circulation, suggesting a more potent anti-tumor reaction.
- the therapeutic potential of the ORFV-containing combination treatment is evaluated by analysis of tumor burdens and animal survival rate of the testing subjects.
- Other viral species for evaluation include, but are not limited to, species within the poxviridae family, for example, a vaccinia virus (VACV), named POV-801 in this invention.
- VACV vaccinia virus
- OV treatment alone usually exhibits low antitumor efficacy, in terms of both the population response rate and individual patient recovery, which has been observed in both in preclinical and clinical studies (Kim, Gene Ther. 8(2): 89-98, 2001 ; Kelly & Russell, Mol. Ther. 15(4), 651-59, 2007; Burke et al., Curr. Opin. Virol. 13:55-60, 2015; Harrington et al., Expert Rev. Anticancer Ther. 15(12): 1389-403, 2015; Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015; Patil et al., J Contemp. Dent. Pract.
- the gut commensal bacteria are evaluated for augmenting the antitumor activity of the selected OVs.
- the gut bacteria genus is Bifidobacterium . Certain bacterial species within this genus have also been used to ameliorate clinical symptoms of irritable bowel syndrome and inflammatory and necrotizing enterocolitis (Ng et al., Inflamm. Bowel Dis.
- Bifidobacterium 's potential augmenting effects to a selected OV are evaluated in preclinical studies.
- in viro monitoring of Bifidobacterium is performed using a modified terminal restriction fragment length polymorphism (T-RFLP) analysis of test subject's fecal samples (Nagashima et al., Biosci. Microflora. 25: 99-107, 2006).
- T-RFLP modified terminal restriction fragment length polymorphism
- the physiological effects of Bifdobacterium may also be evaluated using various in vitro assays.
- the augmenting effect of Bifidobacterium is assessed by comparing the tumor burden and survival rate of the test subjects treated with OV by itself as well as OV with Bifidobacterium .
- Other gut commensal bacteria species for evaluation include, but are not limited to, those published by the World Gastroenterology Organization or species discovered through the disclosed hierarchical clustering studies.
- the immunomodulatory effects of herb extracts or medicines that can regulate the composition and function of the gut commensal bacteria species are tested.
- human clinical trials of successful agent-containing combination OV therapy are designed following the completion of pre-clinical studies.
- enrolled patients are unresponsive to current antitumor therapies and are potential “elite responders” based upon the disclosed hierarchical clustering analysis platform.
- the OV is administered to human subjects about one week to two months after the gut commensal bacteria are administered. In a preferred embodiment, the OV is administered to human subjects about one month after the gut commensal bacteria are administered.
- the oncolytic virus is administered about one to two weeks after the gut commensal bacteria are administered. In some embodiments, an effective amount of the gut microbiota is from about 10 9 to 10 11 cfu. In still other embodiments, an effective amount of the oncolytic virus is from about 10 5 to 10 10 pfu.
- CCTCC Deposit No. V201713 was made on behalf of Minjie Hu on Mar. 28, 2017. This deposit was made and will be maintained in accordance with and under the terms of the Budapest Treaty with respect to seed deposits for the purposes of patent procedure.
- the combination therapies are evaluated in human disease, particularly cancer.
- human cancers There are more than 200 types of human cancers (ACS (2015) Global Cancer Facts & Figures).
- Some cancer types contain a high degree of de novo mutations, which encode neoantigens of the clinical failure key drivers.
- Certain neoantigens that reside in the cells of spatially separated intratumoral subclones within a solid tumor are released out upon OV's oncolysis.
- the released neoantigens could be presented by a set of antigen presenting cells (APC), like the dendritic cell (DC), and a whole panel of immunity against these neoantigens will be initiated, leading to a potent eliminating action to all the existing cancer cells harboring different neoantigens.
- APC antigen presenting cells
- DC dendritic cell
- the method is used for, but not limited to, high mutation cancer types including melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, and renal cancer.
- Melanoma and lung cancer patients compared to patients with other types of cancers, respond favorably to immune checkpoint inhibitors (Ipilimumab, Nivolumab, and Pembrolizumab) and to the oncolytic virus therapy T-VEC, which manifests through prolonged survival rates.
- the combination therapy is used to treat lung cancer.
- the combination therapy is used to treat high-mutation cancer types.
- the combination therapy is used to treat cancer types having normal or low mutation rates.
- antitumor responses are evaluated in preclinical studies using selected animal models.
- Various murine models that have been developed to examine responses to a developing therapy may be used herein. These experimental mouse models include, but are not limited to, models falling within three main categories: transplantable tumors, genetically engineered/transgenic models, and humanized mouse xenograft models.
- Transplantable tumor models are the most widely used in cancer preclinical studies due to rapid output.
- transgenic models confer greater phenotypic variability
- xenograft experiments are usually performed in either nude or severe combined immunodeficiency (SCID) mice that are deficient in adaptive immunity.
- pre-clinical evaluation of the disclosed combination therapies are evaluated in multiple tumor models.
- transplantable models are designed to observe the adaptive immune response.
- mouse strains have the identical genetic backgrounds to that of the transplanted cancer cell lines.
- An example of this transplantable model is C57BL6 house mice challenged intravenously with a murine B16-F10 melanoma cancer cell line to create a lung metastasis cancer model whose adaptive immune response can be monitored.
- the tumor-bearing animals of the transplantable model studies are administered with or without the selected augmenting agent, followed by application of the testing OV, and harvesting and processing their lungs for tumor burden analysis, as shown in FIG. 11 this invention.
- a fluorescently labeled human lung cancer cell line including but not limited to A549, is engrafted subcutaneously into the flank of a nude mouse strain, including but not limited to CD1, to create a human lung cancer xenograft model.
- the murine B16-F10 melanoma cell line was subcutaneously injected into the right flank of a C57BL/6 mouse, and tumor volumes are measured using digital calipers following administration of the augmenting agent and the testing OV, as shown in FIGS. 6,7,8 .
- the augmenting immune responses are initially assessed by counting total numbers of splenic NK, DC, and CD8 T cells or by analyzing the expression levels of certain lymphocyte activation markers (e.g. CD69, CD80 and CD 86) and immune responding cytokines (e.g. interleukin-1 ⁇ (IL-1 ⁇ ), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2, IL-6, TNF- ⁇ and IFN- ⁇ ) before and after agent administration.
- IL-1 ⁇ interleukin-1 ⁇
- GM-CSF granulocyte-macrophage colony-stimulating factor
- IL-2 granulocyte-macrophage colony-stimulating factor
- TNF- ⁇ and IFN- ⁇ TNF- ⁇
- the tumor burden and animal survival analysis are assessed.
- preclinical tumor models for other types of cancers are created and used to evaluate the disclosed combination therapies. Data generated from the preclinical studies provide useful safety and efficacy information about the disclosed
- the augmenting bacterial agents are obtained from a commercial resource or human fecal samples.
- commercially obtained bacteria in live forms are expanded on reduced clostridial medium (RCM) agar in anaerobic conditions.
- the bacteria obtained may be formulated in phosphate-buffered saline (PBS) at 5 ⁇ 10 6 c.f.u/ ⁇ l.
- PBS phosphate-buffered saline
- a starting dose of 200 ⁇ l formulated bacteria is administrated to each mouse through oral feeding based on published data (Sivan et al., Science 350(6264): 1084-89, 2015).
- the total amount of formulated bacteria is given either in a single dose or in multiple doses spread out over several days (e.g. 14 days), and the frequency and duration of dose administration is determined.
- the oncolytic viruses are formulated either in PBS with 10% v/v glycerol or in 30 mM Tris with 10% (w/v) sucrose at a viral concentration of 10 5 p.f.u/ ⁇ l.
- an initial dose of 10 7 p.f.u. is administered to each mouse based on published data (Rintoul et al., Mol. Ther. 20(6): 1148-57, 2012).
- the viral formulation is administered either locally or systemically, depending on the animal model. Since the first OV drug T-Vec was successfully delivered through local injection (Harrington et al., Expert Rev. Anticancer Ther.
- the same approach can be used in this invention.
- up to five doses of 100 ⁇ l viral formulation are injected intratumorally at different time points, and the treated tumors are measured 2-3 times per week using digital calipers.
- Systemic delivery has the benefit of evaluating adaptive immune response, which is critical for treating a metastatic tumor.
- mice are treated intravenously with five doses of 100 ul viral formulation and are monitored for signs of organ distress.
- the selected bacterial agent(s) and the chosen oncolytic virus(es) may be formulated as an ingredient in a pharmaceutical composition separately.
- the compositions may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives and various compatible carriers.
- the proportion and identity of the pharmaceutically acceptable diluent depends on the chosen route of administration, compatibility with a live virus and, where applicable, compatibility with the stability of the immune-augmenting agent. Starting doses of 3 ⁇ 10 7 c.f.u. kg ⁇ 1 of the selected bacterial agent and 1 ⁇ 10 7 p.f.u. kg ⁇ 1 of the chosen virus in formulated forms are used based on published clinical studies (Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015; Waller et al., Scand. J. Gastroenterol.
- the formulated virus is diluted in bicarbonate-buffered saline in a total infusion volume of 50 ml immediately before intravenous infusion, and is infused over the course of 60 min. Tumor response is assessed by contrast-enhanced computed tomography (CT) imaging, maximum tumor diameters, and Hounsfield units (Breitbach et al., Nature 477, 99-102, 2011).
- CT computed tomography
- the current invention also aims to build a platform for the selection of elite responders to individual OV therapy.
- fecal samples are collected from a group of 60 consented subjects divided into three categories: cancer patients, non-disease subjects in a high-risk population, and healthy subjects in a low-risk population.
- the microbial DNA in each sample is purified with methods modified from the protocol of American Human Microbiome Project (HMP) (Wesolowska-Andersen et al., Microbiome, 2, 19, 2014). Following DNA purification, the quality of the DNA is checked with a spectrophotometer, and only DNA with a 260 nm/280 nm ratio higher than 1.8 is subject to 16S ribosomal RNA target sequencing or metagenomic sequencing.
- HMP American Human Microbiome Project
- PCR amplification of the 16S RNA gene is conducted with primers designed based on the conserved regions across all bacterial strains, and the PCR products are purified with the QiaQuick PCR purification kit from, but not limited to, Qiagen.
- the PCR-amplified 16S ribosomal RNA (rRNA) target sequencing is performed.
- the abundance of species-specific sequences of the variable regions of rRNA is utilized for clustering analysis.
- metagonomic sequences enable exploration of thousands of species.
- reads from metagenomic sequencing are mapped to the strain-specific sequences from the bacterial genome databases built from 3000 reference genomes (Grice & Segre, Annu.
- the reference genomes are indexed with a Burrows-Wheeler index.
- the mapped data are normalized based on the length of reference sequences and total read counts.
- the calculated abundances of bacterial strains are further subjected to clustering analysis.
- the bioinformatics tools developed by R statistic programming are used to generate a taxonomic tree (Segata et al., Nat. Methods, 9(8); 811-14, 2012) and an enterotype cluster for each person.
- tumor-bearing mice are individually pre-treated with each collected human fecal sample, followed by a treatment with a chosen OV (e.g. ORFV).
- OV e.g. ORFV
- one platform is built for selection of potential elite responders to the chosen OV.
- the number of human participants is increased to build similar platforms for other OV therapies.
- new gut commensal bacteria species may be identified during the comparison analysis.
- the elite responder selection platform can facilitate the development of personalized precision medicine.
- Gut microbiota “gut commensal bacteria,” “gut microbes.” or “GM” refer to an ensemble of microorganisms that reside in various organs, preferably the intestines and/or stomach. Gut microbiota contain tens of trillions of microorganisms. In some embodiments, gut microbiota are common to most individuals, while in other embodiments, gut microbiota are specific to an individual.
- anticancer activity or “antitumor activity” refers to the ability of an agent to kill cancer cells, decrease the severity of the cancer, or block or prevent the cancer from spreading.
- an “effective amount” of an oncolytic virus is meant as an amount sufficient, upon single or multiple dose administration, to treat a cancer cell, prolong or prevent advancement of the cancer (e.g. prevent additional tumor growth of a cancer, prevent additional inflammatory response), ameliorate, alleviate, relieve, or improve a subject's symptoms of the cancer beyond that expected in the absence of such treatment.
- the amount of oncolytic virus required may depend on the particular virus given, the type of cancer being treated, the route of administration, and the length of time required to treat the cancer.
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the oncolytic virus, the age, body weight, general health, sex, diet of the patient, time of administration, rate of excretion, drug combinations, the judgment of the treating physician, and the severity of the particular cancer being treated.
- the amount of additional oncolytic virus present in a composition of this invention typically will be no more than the amount that would normally be administered in a composition comprising that oncolytic virus as the only active agent.
- Pre-condition refers to a process of administrating a set of gut microbes to test subjects ahead of OV treatment.
- the intake of gut microbes interrupts the subjects immunological equilibrium that pathologically favors tumor progression.
- the gut microbes also enhance the subject's immune system to recognize tumor-specific signals released from OV-targeted cells.
- a systematic immunological response to tumor loci is boosted after administration of gut microbes.
- intramoral refers to the space within a tumor.
- the mechanism of pre-conditioning is critical for an effective antitumor response.
- a “pre-conditioned” state facilitates the killing of metastatic cancer cells at distant sites previously unseen by a virus and intratumoral bystanders localized outside of the infected area.
- An “effective amount” of a gut microbiota is an amount sufficient to create the “pre-condition,” and thus facilitates an effective antitumor response.
- a specific bacterial strain is purified by separation of a single bacterial colony from the bacterial culture.
- a starting probiotic material containing several bacterial strains was cultured with serial dilutions on solid agar culture plates. These plates contained well-separated colonies, from which single colonies were picked up, each representing individual strains. Each picked colony was streaked onto fresh plates and incubated for 24-72 hours (strain-dependent) at 37° C. to allow the formation of a new individual colony. The process was repeated multiple times to ensure that the bacteria within a colony originated from a single clone. The final colonies were used to expand the selected bacterial strains.
- the culture chambers of a Work Station were filled with mixed gases.
- the components of the mixed gases are nitrogen (80-90%), carbon dioxide (5-10%) and hydrogen (5-10%).
- the catalyst palladium (Pd) was used to remove the trace oxygen by enabling a reaction between oxygen and hydrogen.
- An autoclaved culture broth was continuously flushed by filtered nitrogen gas for 30-60 minutes until the color of the oxygen indicator (0.3% resazurin) changed from pink to colorless.
- the de-gassed broth bottle was then capped and sealed with parafilm to prevent air leakage. All the broths were used within the culture chamber of a Work Station.
- a strain stock 100 ⁇ l of a strain stock was inoculated into a 50 ml centrifuge tube containing 50 ml of a liquid culture broth, followed by incubation at 3?° C. between 24-72 hours (strain-dependent). The 50 ml culture was then transferred into a 1 liter glass bottle containing 1000 ml of liquid culture broth, and allowed to continue growth at 37° C. between 24-72 hours.
- the growth property of each selected strain was evaluated by performing growth curve experiments. 3 ml sample was taken from a 50 ml tube containing 50 ml bacterial culture at sequential time points, and OD (optical density) value at 600 nm was measured by a plate reader. A growth curve for each strain was plotted (OD read vs. time) and the log growth phase for each strain was determined. The log phase culture of each strain was used for the preparation of animal administration solutions.
- a serial dilution culture was set up.
- a glycerol stock of a bacterial strain was serially diluted to the concentrations of 10 ⁇ , 10 2 ⁇ , 10 3 ⁇ , 10 4 ⁇ , 10 5 ⁇ , 10 5 ⁇ , 10 6 ⁇ .
- the diluted bacteria were cultured on solid agar plates. The number of the colonies on each plate was counted and the titer of original bacterial stock was calculated by multiplying the count and dilution factor.
- All the tubes containing individual administration solution were filled with nitrogen gas and kept at room temperature less than 60 minutes before animal administration.
- the genomic sequences from different species can provide distinguishing signatures for species differentiation.
- the 16S rRNA gene sequence can fulfill the task with integrative homologous and clustering analysis of its hypervariable regions (V1-V9).
- the 16S rRNA gene was amplified by the polymerase chain reaction (PCR) with the primers: 5CGG GGG TGC TGC CCA CTT TCA TG3′ and 5′GCT TGT TGG TGA GGT AAC GGC T3′.
- the PCR product then underwent Sanger sequencing. The sequences started from both ends were processed for assembly of the 16S rRNA gene.
- sequences were compared to the microbial genome databases from the NCBI (National Center of Biotechnology Information at National Institute of Health) with the Blastn computational program, and the species with high sequence identity and homology (>99%) to the query sequences in the hyper-variable regions were identified.
- qPCR is used as a pre-condition screening with an identified panel of strain specific primers.
- the quantification of the abundance of rRNA genes in feces could infer the bacterial composition in the gastrointestinal tract.
- the PCR amplification curve for the panel of bacterial species is utilized for the evaluation of the species composition in the feces.
- the composition is used to classify the subtypes of tumor bearers.
- Genomic DNA is extracted from samples using the Mo Bio Powersoil®-htp 96 Well Soil DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, Calif.) or the QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, Calif.).
- the thermo-cycling conditions are set as follows: 95° C. for 2 minutes followed by 45 cycles of 95° C. for 3 seconds, 60° C. for 30 seconds, and subsequent measurement of FAM channel fluorescent readings.
- the hyper-variable regions (V3, V4 and V5) of the microbial 16S rRNA gene contain unique strain-specific sequences that can be utilized for studying the microbial lineages. With integrative bioinformatics analysis, phylogeny and taxonomy of the gut microbial species can be elucidated.
- the microbial genomic DNA was purified from fecal pellets collected from experimental mice and subject to the high throughput 16S ribosomal RNA (rRNA) gene sequencing by the Illumina sequencing platform. Below is a description of the sequencing data processing.
- the fecal samples from the tumor bearing mice were collected for the bacterial DNA purification.
- the fecal samples were collected from normal untreated mice as controls, microbial treated, and oncolytic virus treated mice.
- the fecal samples for each mouse are selected at three time points: before microbial administration, before B16 inoculation, and two weeks after the B16 inoculation.
- the DNAs were then assessed for the quality control and concentration measurement. Samples passed the quality control are subject to the 16S rRNA gene sequencing downstream.
- the hyper-variable regions of 16S rRNA genes were amplified using the following primers:
- Primer Type Region Name Primer (5′ ⁇ 3′) Bacterial V4 515F GTGCCAGCMGCCGCGGTAA 16S V3 + V4 806R GGACTACHVGGGTWTCTAAT 341F CCTAYGGGRBGCASCAG 806R GGACTACNNGGGTATCTAAT V4 + V5 515F GTOCCAGCMGCCGCGGTAA 907R CCGTCAATTCCTTTGAGTTT
- Sequencing platform generated the reads with 250 bp paired-end (PE) with an average of 10,000 reads per sample.
- the gz-compressed data gzip were transferred through the ftp (file transfer protocol) server.
- the sequencing raw reads were pre-processed by demultiplex step of reads, clip step of barcodes, primers and adaptor clips, joining step of paired-end reads.
- the fastq format was generated for raw reads and pre-processed.
- the quality control tool is used to assess the sequence files to report base sequence quality, GC content, N base level, sequence duplication level, sequence overrepresentation level, and Kmer content.
- the pre-processed sequence reads were subjected to the QIIME pipeline for clustering.
- the sequence reads as input into the pipeline under sequence similarity comparison were then classified into OTUs (Operational Taxonomic Units) with the Greengenes database.
- OTUs Orthogonal Taxonomic Units
- the abundance of the taxonomic units is evaluated. By comparing the differential abundance between samples with different microbial treatments for the tumor progression, the correlation of the OTU and efficiency of each treatment are identified.
- A549 Cells (Prajna code: Cl; originally obtained from BeNa Culture Collection, Cat #BNCC337696) are thawed by transferring a frozen vial containing 2 ⁇ 10 6 cells/ml from a liquid nitrogen tank into a 37° C. water bath.
- Cell culture medium (10% FBS in DMEM) is warmed in a 37° C. water bath.
- the vial surface is thoroughly wiped with 75% alcohol.
- the vial is opened in a cell culture hood and transferred into a 1.5 ml sterile tube with a P1000 pipet. 10 ml of the pre-warmed cell culture medium is slowly added and centrifuged at 230 ⁇ g for 5 min at room temperature (RT).
- the supernatant is decanted and the cells are re-suspended in the cell culture medium.
- the cells are seeded into a 75 cm 2 flask at a cell density of 0.7-2 ⁇ 10 6 /flask and placed into a 37° C. cell culture incubator to allow cell growth.
- the medium is changed the next day.
- the cultured cells are viewed under an inverted microscope and the cell confluency is assessed; if the cell confluence is between 50-80%. the next steps are proceeded with.
- the medium is aspirated and the cell monolayer is rinsed with 10 ml DPBS (without Ca 2+ /Mg 2+ ). 5 ml of 0.25% trypsin/EDTA is added into the rinsed flask. The flask is rotated to make sure that the added trypsin/EDTA covers the cell monolayer. The flask is placed in the incubator for 4-6 minutes. The cells are examined under an inverted microscope to ensure that all the cells are detached and floating. 10 ml of the fresh cell culture medium is added to inactivate the trypsin.
- the cells are re-suspended with a 10 ml pipet.
- the cell suspension is transferred into a 50 ml conical tube and the cells are centrifuged at 230 ⁇ g for 5 min at RT.
- the supernatant is decanted and the cells are re-suspended in about 5 ml of the cell culture medium.
- a small aliquot of cells (100-200 ⁇ l) is removed and the cells are counted with a Life's cell counter.
- the cell density is adjusted to 1 ⁇ 10 6 cells/ml with the cell culture medium.
- the re-suspended cells are seeded into T175 flasks at a cell density of 2 ⁇ 10 6 /flask.
- the flask is placed into a 37° C. cell culture incubator to allow cell growth, and the medium is changed every other day.
- the subculture process is repeated as needed.
- the cultured cells are viewed under an inverted microscope to make sure that the cell confluence is close to 80%.
- the A549 cells are harvested and re-suspended with trypsin/EDTA using the steps described above in “Subculture of A549 cells,” A small aliquot of cells (100-200 ⁇ l) is removed and the cells are counted with a Life's cell counter. The cell viability is examined during cell counting (ideally, the cell viability should be in excess of 90% in order to achieve a good recovery after freezing).
- the cells are centrifuged at 230 ⁇ g for 5 min at RT and re-suspended at a density of 1 ⁇ 10 6 cells per ml in the cell freeze medium.
- the cell suspension is aliquoted into 1 ml aliquots in 2 ml cryogenic vials and the vials are placed into a ⁇ 80° C. freezer for 4 hours.
- the vials are transferred to the gas phase of a liquid nitrogen storage tank and the location of each vial is recorded.
- Virus infection is performed with Prajna code: POV-801, originally obtained from China Center for Type Culture Collection, Cat # GDV117.
- the cultured A549 cells in a 175 cm 2 flask are viewed under an inverted microscope to make sure that the cells have reached confluence.
- the medium is changed and 200 ⁇ l of a viral stock is transferred into the flask.
- the flask is rotated to ensure that the added viral solution completely covers the cell monolayer.
- the flask is placed into a 37° C. cell culture incubator to allow viral infection of A549 cells.
- the viral treated cells are examined every day under an inverted microscope. If over 90% of the cells changed their morphology from a flat to round shape, the infection process is complete.
- Infected A549 cells are viewed under an inverted microscope to ensure that the infection process is complete.
- the culture medium is transferred into a 50 nil conical tube and washed with DPBS. 3 ml 0.25% trypsin/EDTA are added and the flask is placed into a 37° C. incubator for 3 minutes. A small volume of fresh cell culture medium is added to inactivate the trypsin.
- the cells are centrifuged at 3000 rpm for 10 min at RT and the supernatant is aspirated. The pellet is re-suspended with 10 mM EDTA in PBS and the viral stocks are stored at ⁇ 80° C.
- the freezing and thawing of the viral stock is repeated three times.
- the treated viral samples are sonicated for 3 ⁇ 1 minutes.
- the sonicated samples are centrifuged at 230 ⁇ g for 10 min at 4° C.
- the supernatant is transferred into a 15 ml tube and the remaining pellet is re-suspended with PBS.
- the supernatant and suspension are placed into a ⁇ 80° C. freezer.
- Cell medium is aspirated from an A549 confluent T175 flask.
- the cell monolayer is rinsed with 10 ml DPBS (without Ca2+/Mg2+).
- 5 ml of 0.25% trypsin/EDTA are added into the rinsed flask and the flasked is rotated to ensure that the added trypsin/EDTA covers the cell monolayer.
- the flask is placed in the incubator for 4-6 minutes.
- the cells are examined under an inverted microscope to ensure that all the cells are detached and floating.
- 5 ml of fresh cell culture medium is added to inactivate the trypsin.
- the cells are re-suspended with a 10 ml pipet.
- the cell suspension is transferred into a 50 ml conical tube.
- the cells are centrifuged at 230 ⁇ g for 5 min at RT and the cells are re-suspended in 5 ml of the cell culture medium. A small aliquot of cells (100-200 ⁇ l) is removed and the cells are counted with a Life's cell counter. The cell density is adjusted to 1 ⁇ 10 6 cells/ml with the cell culture medium. The cell suspension is diluted into 1 ⁇ 10 5 cells/ml with the cell culture medium. 2 ml of the cell suspension is transferred into each well of a 6-well plate and the plate is swirled to ensure the even distribution of cells in each well. The cells are cultured in a 37° C. incubator for 2 days.
- a stock of the virus to be tittered is thawed on ice.
- a serial dilution of 10 2 , 10 3 , 10 4 , . . . 10 8 is prepared.
- Each well of the cell-seeded 6-well plate is labeled with the corresponding dilution.
- the medium is aspirated from each well.
- a ml of the viral dilution is transferred into its corresponding well and the plate is incubated in a 37° C. incubator for 60 minutes.
- the viral inoculum is removed from each well.
- 2 ml of a freshly made culture medium (2% FBS in DMEM) is added to each well and the plate is incubated in a 37° C. incubator for 2 days.
- mice were separated into two groups: T0: No antibiotic treated and T1: antibiotic treated.
- the mice in both groups had been housed in our SPF facility for 4 days and treated with or without antibiotics for two weeks before 10E6 B16-F10 cells were inoculated subcutaneously. Tumors were measured every day starting from the 10th day after the inoculation. Fecal pellets were collected at two weeks after the B16 inoculation. Data show that tumors generally grow faster on the T1 mice than on most of T0 mice ( FIG. 1 ). This suggests that ablation of gut microbes enhances tumor growth and further implies microbes suppress tumor progression.
- FIG. 2 shows that two samples displayed low levels of bifidobacteriaceae (A9 and A23) in the untreated group T0. The analysis was performed with blinded sample labeling.
- samples A9 and A23 matched the two mice with exceptional tumor growth ( FIG. 3 ).
- the experiment revealed that the bifidobacteriaceae played a role in tumor suppression.
- Test articles include Oncolytic Virus (OV): POV-601: 1 ⁇ 10 8 PFU/mL; POV-801: 1 ⁇ 10 8 PFU/mL.
- POV-601 is from CCTCC Deposit No. V201713.
- POV-801 was obtained from China Center for Type Culture Collection (Wuhan, China, Cat #GDV117). C57BL/6 female mice, aged between 49-62 days. were supplied from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in a standardized animal facility following the Animal Care and Veterinary Services standard operating procedures.
- test article was injected into a testing animal either subcutaneously or intravenously at a dose shown in Table 1. Each testing mouse was weighed and the weight was recorded every day until all the testing mice were sacrificed. The mortality, behavior, and body weight were evaluated everyday.
- An electronic balance (supplied from Mettler, Model: ML1602T) was used to measure the body weight one day before the OV was injected, followed daily. No significant differences in mean body weights were observed among the study groups. No groups had an unintentional decline in body weight more than 5%, therefore, the result of the toxicity tests showed that the viruses had no toxicity to the host ( FIGS. 4A-C ).
- POV-601 is from CCTCC Deposit No. V201713. POV-801 was obtained from China Center for Type Culture Collection (Wuhan, China, Cat #GDV117). PGM-001 was obtained from Seeking Health (Bellingham, Wash., USA, SKU: PBIFIDO-60-CAPS).
- mice C57BL/6 female mice, aged between 49-62 days, were supplied from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in a standardized animal facility following the Animal Care and Veterinary Services standard operating procedures.
- GM was formulated at a density according to the Test and Control Articles, and 200 ⁇ l of GM was orally administrated into each testing animal one day before the B16-F10 cell injection, followed by the schedule listed in Table 2.
- murine B16-F10 melanoma cells harvested from an adherent culture were formulated in PBS at a density of 2 ⁇ 10 6 /cells, 100 ⁇ l of the formulated cells were injected subcutaneously into the right flank of each testing mouse on day 0; and subcutaneous tumors were allowed to grow.
- each tumor site was injected with 20 ⁇ l of either the control (PBS) or the testing OV (POV-601 or POV-801) at a density according to the Test and Control Articles, followed by additional injections at certain time points scheduled in Table 2. All the testing animals were euthanized at day 24 after B16-F10 injection. Those animals whose tumor volume was over 3500 mm 3 were sacrificed before the euthanasia day.
- PBS control
- testing OV POV-601 or POV-801
- Tumor volume L ⁇ W 2 /2.
- Body weight was measured once before OV-injection and four times after each OV-injection. amounting to five times during the experiments. There were no significant differences in mean body weights among study groups ( FIG. 5 ).
- FIG. 6 shows the anti-tumor activity of OV/GM combination in a syngeneic murine melanoma tumor model (Total Mice #: Control: 9; POV-801 only: 13; POV-801-PGM-001:14, Mean ⁇ SE).
- PGM-001 as a pre-condition was orally administrated into the groups PGM-001 only and POV-801+PGM-001 the day before the B16-F10 cells injection, B16-F10 injected into each testing animal on the day 0.
- Tumor-bearing animals were then treated four times subcutaneously (s.c.) with phosphate-buffered saline (PBS) as a control, or treated four times s.c.
- PBS phosphate-buffered saline
- FIG. 7 shows the anti-tumor activity of OV/GM combination in a syngeneic murine melanoma tumor model (Total Mice #: Control: 9; POV-601 only: 13; POV-601+PGM-001:13, Mean ⁇ SE).
- PGM-001 as a pre-condition was orally administrated into the groups PGM-001 only and POV-601+PGM-001 the day before the B16-F10 cells injection, B16-F10-F10 injected into each testing animal on the day 0.
- Tumor-bearing animals were then treated four times s.c. with phosphate-buffered saline (PBS) as a control, or treated four times s.c.
- PBS phosphate-buffered saline
- the tumor volume data was collected on day 24.
- the anti-tumor effects are shown in FIG. 8 and Table 3 below.
- Control or GM administration Control or OV Injection Control 6 PBS: two times for a week before PBS: the first injection was 24 hour B16 injection, followed by weekly after B16 injection, followed at a 48 administration, amounting to 5 hour interval, amounting to 4 times times PGM-001 5 PGM-001: two times for a week PBS: the first injection was 24 hour only before B16 injection, followed by after B16 injection, followed at a 48 weekly administration, amounting hour interval, amounting to 4 times to 5 times POV-601 5 PBS: two times for a week before POV-601: the first injection was 24 only B16 injection, followed by weekly hour after B16 injection, followed at a administration, amounting to 5 48 hour interval, amounting to 4 times times POV-601 + 5 PGM-001: two times for a week POV-601: the first injection was 24 PGM-001 before B16 injection, followed by hour after B16 injection, followed at a weekly admins stration, amounting 48 hour interval, amounting to 4 times to 4 times to
- POV-601 is from CCTCC Deposit No. V201713. POV-801 was obtained from China Center for Type Culture Collection (Wuhan, China, Cat #GDV117). PGM-001 was obtained from Seeking Health (Bellingham, Wash., USA, SKU: PBIFIDO-60-CAPS).
- mice C5713L/6 female mice, aged between 49-62 days, were supplied from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in a standardized animal facility following the Animal Care and Veterinary Services standard operating procedures.
- GM was formulated at a density, and 200 ul of GM was orally administrated into each testing animal two times for a week before the B16-F10 cell injection, followed by the schedule listed in Table 4.
- murine B16-F10 melanoma cells harvested from an adherent culture were formulated in PBS at a density of 3 ⁇ 10 6 /cells, and 100 ⁇ l of the formulated cells were injected intravenously into each testing mouse on day 0. Lungs were excised and surface metastases were counted on day 10 or 14.
- each testing animal was injected with 100 ⁇ l of control (PBS) or the testing OV (POV-601) at the titers shown in the Test and Control Articles section, followed by additional injections at certain time points scheduled in Table 4.
- PBS control
- POV-601 testing OV
- one mice from the control group were euthanized, and its lung was harvested and examined for tumor formation. In the case that there were few tumors formed on the lung surface, all the testing animals would be euthanized on Day 14.
- Body weight was measured twice (days ⁇ 9 and 0) before OV-injection and five times on days 2,5,7,11,15, amount to seven times during the experiment. There was no significant changes in mean body weights among all the study groups. ( FIG. 9 ).
- mice from all groups were euthanized at day 14 after the B16-F10 injection. Through dissection, the spleens of all mice were removed and measured respectively (in grams). No significant differences in mean spleen weights among study groups were observed ( FIG. 10 ).
- FIG. 11 shows the results of the control, PGM-001 only, POV-601 only, and POV-601+-PGM-001 treatment groups.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Therapeutic methods for administering gut microbiota and oncolytic viruses to a subject are provided. The gut microbiota serve to pre-condition, the subject's immune system to antitumor responses and augments anticancer activity of the oncolytic vims. Combinations of the gut, microbiota and viruses and uses thereof for treating and preventing cancer are provided. The present disclosure also provides methods for building elite responder selection platforms through hierarchical clustering analysis of genomic profiles for human gut microbiome.
Description
- This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 62/390,395 filed Mar. 28, 2016. The contents of this application are herein incorporated fully by reference.
- The present disclosure provides methods for administering to a subject gut microbiota and oncolytic viruses. Combinations of the viruses and gut microbiota and uses thereof for treating and preventing cancer are also provided.
- Cancer consists of a group of diseases marked by uncontrolled growth of malignant cells. There are over one hundred cancers that affect a large segment of the human population and account for about 13% of all fatalities. Cancer was responsible for over 8.2 million deaths worldwide in 2012, and this number is predicted to jump to 13 million by 2030. The number of new cancer cases diagnosed in 2012 worldwide was 14.1 million, and 58% of new cancer cases are found in developed countries like the US. Among
children ages 0 to 14, an estimated 163,300 new cases were diagnosed in 2012, of which about 80,000 resulted in death (WHO, World Health Report 2014; National Center for Health Statistics, 2014; ACS. Global Cancer Facts & Figures, 2015). - Current existing cancer therapies include radiation, surgery, chemotherapy, targeted therapy, immune therapy, oncolytic-virus (OV)-based therapies, or a combination of the above (ACS, Global Cancer Facts & Figures, 2015). Patient response to therapy depends on the specific cancer type, the disease stage, and the particular therapy being used, which may determine the patient's total survival time (National Center for Health Statistics, 2014). Unfortunately, only a small minority of patients can be completely cured with one of the above therapeutic treatments (WHO, World Health Report, 2014). Cancer metastasis, the translocation of the primary cancer from its origin into other parts of the body, is often associated with the late stages of a cancer and results in the most cancer deaths (National Comprehensive Cancer Network, What is Metastasized Cancer?, 2016). Cancer is highly linked to old age (Coleman & Rubinas, Elsevier Academic Press, p. 66, 2009), which highlights the urgency for developing an effective therapy due to our aging population.
- Recent technical advancements in DNA sequencing and bioinformatics have made it possible to carefully analyze genomic aberration profiles of samples from different patients. These analyses have uncovered the extensive inter-patient and intra-tumor heterogeneity and ongoing clonal adaptation in human tumors, which contain spatially and temporally separated and role-changing subclones with different driver and passenger mutation landscapes (Lipinski, Trends Cancer 2(1): 49-63, 2016). This discovery indicates that cancer is a randomized and evolving process, with its mutation load changing in number and composition clone-to-clone or even cell-to-cell within a given tumor (Shlien et al., Nat. Genet 47, 257-262, 2015). This may affect the varying responses to therapies for individual cancers, and explains the development process of drug resistance and certain clinical failures. This phenomenon certainly questions the feasibility of a widely used therapy strategy, which treats dynamically evolving tumor ‘organisms’ through precise molecular targeting, and begs the need for a more systemic approach. “Precise therapies” as those with defined molecular targets, which include most chemotherapies, humoral immunotherapy using monoclonal antibodies, and the recent advanced chimeric antigen receptor T (Car T) cell therapy. On the other hand, “systematic treatments” are those whose efficacy relies on the systemic activation of the host immune system, including immune cell therapy (CIK, NK, TIL et al.), checkpoint inhibitor therapy, and OV therapy. Responses from “precise therapies” tend to be relatively transient, while “systematic treatments” usually give good levels of long-term responses, which could translate into long-term survival.
- Checkpoint inhibitor therapy acts by modulating the host systemic immune response (La-Beck, Pharmacotherapy 35(10): 963-76, 2015; Rubin, Clin J Oncol Nurs. 19(6):709-17, 2015; Sharma & Allison, Science 348(6230): 56-61, 2015). The clinical efficacy of checkpoint inhibitor therapy in regulating either the key T cell priming player—the cytotoxic T lymphocyte antigen-4 (CTLA-4)—or the major T cell function suppressors—the programmed cell death protein-1 (PD-1) and its ligand PDL-1—led to FDA approval of these antibodies for treatment of metastatic melanoma (MM) and other solid tumors (Hodi et al., N Engl. J. Med 363, 711-23, 2010; Prieto et al., Nat. Rev. Gastroenterol. Hepatol. 12, 681-700, 2015). However, only a subset of patients respond to the antibody treatments, and the efficacy with any single therapy remains limited (Chodon et al., Immunol Invest. 44(8): 817-36, 2015). In addition, only a 50% response rate (which translates to a 22% complete response rate) has been reported, even in combination with the oncolytic virus T-Vec (Puzanov et al., J. Clin. Oncol. 33, S9063, 2015). On the other hand, patients with ongoing intratumoral T cell response before therapy usually respond more frequently to the antibody treatment (Ji, Cancer Immunol Immunother. 61(7): 1019-31, 2012; Gajewski, Cancer J. 16(4): 399-403, 2010; Tumeh, Nature 515(7528): 568-71, 2014). In addition, mice fed with antibodies showed a significant decease in the activation of both CD4+ T effector cells and CD8+ tumor infiltrating lymphocytes (TIL), which play a critical role in the adaptive immune response during antibody-initiated tumor killing. There remains a need in the art to improve upon this therapy by enhancing the immune response in the intratumoral space. Therefore, among the objects herein, it is an object to provide therapeutic methods that pre-condition a subject's immune system to antitumor responses and augment the anticancer activity of existing anti-cancer “systematic treatments.”
- Oncolytic viruses (OV) are therapeutically used microbes (either naturally occurring or genetically-engineered) that preferentially infect and replicate in cancer cells in order to eliminate malignant tumors while avoiding toxicity (Seymour & Fisher, Br. J Cancer 114(4): 357-61, 2016; Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015; Turnbull et al., Viruses 7(12): 6291-312, 2015; Larissa et al., Trends Cancer 1(4): 266-77, 2015). Oncolytic viruses target tumor cells precisely because the same genetic alterations that allow malignant tumor cells to proliferate and survive also promote the growth of lytic viruses (Hanahan & Weinberg, Cell 144(5): 646-74, 2011; Miest & Cattaneo, Nat. Rev. Microbiol. 12(1): 23-34, 2014; Burke et al., Curr. Opin. Virol. 13: 55-60, 2015). Additionally, drug-resistant cancer cells and cancer stem cells retain their susceptibility to OV, which are effective in the hypoxic environments characteristic of solid tumors (Shen & Hermiston, Gene Ther. 12, 902-10, 20051. Infected OV have the ability to coordinate cancer cell death at a suitable time point within the virus life cycle, which leads to the release of infectious viral particles (Seymour & Fisher, Br. J. Cancer 114(4): 357-61, 2016). OV-initiated tumor cell death not only raises the active intratumoral viral dose that infects more tumor cells, but also releases significant amounts of tumor-specific neoantigens that can be presented by intratumoral antigen presenting cells (APCs), such as activated DCs. These cells ignite a host systemic antitumor immune response, a second mechanism of cancer cell killing beyond the direct in situ viral lysis of the tumor (Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2014). This second mechanism is important for an effective antitumor response, as it will also kill metastatic cancer cells at distant sites previously unseen by the virus as well as intratumoral bystanders localized outside the infected area.
- Research into the therapeutic potential of OV started in the 1950s (Huebner et al., Cancer 9, 1211-218, 1956), with clinical trials being held shortly after for a range of cancers (e.g. melanoma, squamous cell carcinoma of the head and neck (SCCHN), pancreatic cancer, ovarian cancer, colorectal cancer, glioma, non-small cell lung cancer (NSCLC), myeloma, breast cancer, prostate cancer, bladder cancer, mesothelioma, hepatocellular carcinoma, and pediatric tumors) with documented therapeutic benefit during the past decade (Kim, Gene Ther. 8(2): 89-98, 2001; Kelly & Russell, Mol. Ther. 15(4), 651-59, 2007; Eisenstein et al., Oncolytic Virother. 3: 83-91, 2014; Miest & Cattaneo, Nat. Rev. Microbiol. 12(1): 23-34, 2014; Patil et al., J. Contemp. Dent. Pract. 16(8): i-ii, 2015; Burke et al., Curr. Opin. Virol. 13: 55-60, 2015; Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015). One example is the T-Vec clinical trials, which gave statistically significant improved durable responses and heightened survival rates in patients with unresectable melanoma, expediting FDA approval of the first OV drugs (Andtbacka et al., J. Clin. Oncol. 33.25: 2780-00, 2015) While the best OV T-Vec trial showed promising results, there are still a host of problems that need to be addressed. In the 436 Phase III trials, only a 16.3% durable response rate and a 26.4% objective response rate were observed, with only 10.9% of the participants achieving a complete response (Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015).
- OV has been used in more than 40 clinical trials to treat a spectrum of human malignancies, and one particular therapy has been successfully translated into the first FDA-approved OV drug (Harrington et al., Expert Rev. Anticancer Ther. 15(12): 1389-403, 2015). Despite its preliminary success, the efficacy and responsiveness rates across all OV trials remain disappointingly low, especially when factored into the overall survival rate (Buijs et al., Hum. Vaccin. Immunother. 11(7): 1573-84, 2015; Burke et al., Curr. Opin. Virol. 13: 55-60, 2015; Harrington et al., Expert Rev Anticancer Ther. 15(12): 1389-403, 2015; Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015: Patil et al., J. Contemp. Dent. Pract. 16(8): i-ii, 2015; Puzanov et al., J Clin. Oncol. 33, S90632015; Turnbull et al., Viruses 7(12): 6291-312, 2015). This could be partially derived from the highly suppressive microenvironment within a solid tumor (de Vries et al., Cancer Gene Ther. 22(4):169-71, 2015; Church & Galon, Immunity 43(4): 631-3, 2015; Clarke, Immunotherapy 8(2): 103-6, 2016), which prohibits the OV-initiated adaptive and innate systemic immune responses. It could also be due to the lack of a pre-conditioned anti-tumor immunity by a high percentage of patients, resulting in the low response rates for most systemic anticancer therapies. Therefore, a need exists to develop methods that will increase response rates across all populations.
- Commensal gut bacteria have been used as a nutraceutics, such as the probiotic in fermented food containing the Bifidobacterium genus within the Gram-positive actinobacteria phylum (Hill et al., Nat. Rev. Gastroenterol. Hepatol. 11: 506-14, 2014). It has also been used in routing clinical surgery though fecal microbiota transplantation (FMT) (NICE Interventional Procedure Guidance: 485, 2014). The composition of gut microbiota is regulated by the host's adaptive immune system component secretory immunoglobulins A (sIgAs) (Fransen et al., Immunity 43(3): 527-40, 2015). With the aid of several large projects, like the Human Microbiome Project (HMP) (Backhed et al., 2012) and the International Human Microbiome Consortium (IHMC), the understanding of the composition and functions of the human gut microbiota has increased dramatically in the post-metagenomic era (Segata et al., Genome Biol. 13:R42, 2012; Segata et al., Nat. Methods, 9(8): 811-14, 2012). There are about 100 trillion bacterial cells in the human gut, and they can be categorized into five major phyla, of which approximately 160 species live in the large intestine of any individual (Rajilic-Stojanovic et al., FEMS Microbiol. Rev. 38: 996-1047, 2014; Segata et al., Genome Biol. 13:R42, 2012).
- Unrelated individuals usually do not share similar gut microbiota profiles (Segata et al., Genome Biol. 13:R42, 2012; Segata et al., Nat. Methods, 9(8): 811-14, 2012) and these differences could reflect differences in immune responses. An individual's gut microbiome can be analyzed by two methodological approaches: 16S ribosomal RNA sequencing (Eckburg et al., Science, 308(5728): 1635-38, 2005; Hayashi et al., Microbiol. Immunol. 46(8): 535-48, 2002; Turnbaugh et al., Nature 457(7228): 480-84, 2009) or metagenomic sequencing (Segata et al., Nat. Methods, 9(8): 811-14, 2012). Further data analysis can be used to generate cluster signatures of enterotypes clusters (Culligan et al.,
Virulence 5, 399-412, 2014; Koren et al., PLoS Comput. Biol. 9: e10028632013). - A key aspect of the present invention is to employ commensal gut bacteria to pre-condition a subject's immune system to the anticancer activity of OV therapy. Provided herein are methods and combination therapies using gut microbiota to augment the anticancer potential of OV therapy. By using the augmenting commensal gut microbiota approach disclosed herein, this invention can address the boosts that are necessary for the durable response and complete response rates.
- The present disclosure provides therapeutic methods for treating and preventing cancer by augmenting systematic treatments through certain commensal gut bacterial genera, including, but not limited to Bifidobacterium and Bacteroides, which can potentially boost systemic immune response within the host. These species exhibit significant anti-tumor synergies with checkpoint inhibitors CTLA-4, PD-1/or PDL-1 antibodies when tested in melanoma and colon cancer models or analyzed using melanoma patient samples. Checkpoint inhibitor therapies work by modulating the systemic immune response, one of the two mechanisms underlying OV-based therapies. This invention provides novel methods and combination therapies using OV and commensal gut bacteria species, whose composition in a patient's gut can be further modulated by herb medicine or extracts. This invention also provides methods for building elite responder selection platforms through hierarchical clustering analysis of genomic profiles for human gut microbiome. This invention is applicable to other live therapies (e.g. somatic cell and stem cell therapies), where efficacy relies on systemic activation of the host immune system.
- In some embodiments, the present disclosure provides a method of treating and/or preventing cancer comprising administering to a subject an effective amount of gut microbiota, and administering to the subject an effective amount of an oncolytic virus having anticancer activity and that selectively targets tumor cells, wherein the gut microbiota pre-conditions the subject's immune system to antitumor responses and augments the anticancer activity of the oncolytic virus. In certain embodiments, the oncolytic virus is a virus within the poxviridae family. The oncolytic virus may be, but is not limited to, an orf virus, bovine popular stomatitis virus, pseudocopox virus, or vaccinia virus. In preferred embodiments, the gut microbiota is the genus Bifidobacterium.
- Therapeutic methods are provided for the treatment and/or prevention of cancer, including tumor treatment, and treatment for inflammatory conditions. In some embodiments, the cancer is a type of cancer having a high degree of de novo mutations. Preferably, the cancer is melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, or renal cancer.
- In some embodiments, the oncolytic virus is administered to a subject from about one week to two months alter the gut microbiota is administered. Preferably, the oncolytic virus is administered about one month after the gut microbiota is administered. In the methods and uses provided herein, the subject is an animal. Animals can be non-human animals, mammal, or can include humans. In some embodiments, gut microbiota is administered to human subjects at an effective amount of about 109 to 1011 cfu. The OV may be administered to human subjects at an effective amount from about 105 to 1010 pfu.
- The methods and kits provided herein rely on a pre-condition created by the gut microbiota to enhance the anticancer activity of the oncolytic virus. In some embodiments, the anticancer activity of the OV is synergistically enhanced by the gut microbiota. The critical pre-condition for an effective antitumor response is an enhanced immune response, which may be achieved through commensal gut microbiota augmentation, one of the key concepts of this current invention.
- In certain embodiments, a platform is used to identify potential elite responders to the cancer treatment based on an abundance of the subject's particular gut microbiota. The platform is built through hierarchical clustering analysis of genomic profiles of the human gut microbiome. The platform identifies gut microbiota that suppress tumor progression. The pre-screened subject is predicted to respond favorably to an oncolytic virus based on the abundance of the subject's particular gut microbiota.
- In some embodiments, combination therapies using gut microbiota and OV therapies are packaged as a kit. The packaged kit may contain instructions for administration and other reagents for administration. In certain embodiments, a kit is provided for the treatment of cancer, comprising a pharmaceutical composition comprising gut microbiota that pre-condition a subject's immune system to antitumor responses, a pharmaceutical composition comprising an oncolytic virus having anticancer activity and that selectively targets tumor cells, instructions for sequentially administering the gut microbiota and oncolytic virus, and wherein the gut microbiota augments the anticancer activity of the oncolytic virus. In some embodiments, the kit is used where the cancer is a type of cancer having a high degree of de novo mutations. The cancer may be melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, or renal cancer. The kit may also comprise the gut microbiota, Bifidobacterium.
-
FIG. 1 shows that tumor growth is influenced by the ablation of gut microbes. -
FIG. 2 shows a heatmap of 16S rRNA gene sequencing. -
FIG. 3 shows tumor growth curves for mice without antibiotic treatment. -
FIGS. 4A-C show that oncolytic viruses had no toxicity to the host. -
FIG. 5 shows no significant differences in mean body weights among study groups in the evaluation of the anti-tumor activity of OV/GM combination in a murine melanoma tumor model. -
FIG. 6 shows the synergistic anti-tumor activity of an OV/GM (POV-801+PGM-001) combination in a syngeneic murine melanoma tumor model. -
FIG. 7 shows the synergistic anti-tumor activity of OV/GM (POV-6014 PGM-001) combination in a syngeneic murine melanoma tumor model. -
FIG. 8 shows the synergistic anti-tumor effects of various OV/GM combinations in a syngeneic murine melanoma tumor model. -
FIG. 9 shows no significant differences in mean body weights among study groups in the evaluation of the anti-tumor activity of OV/GM combination in a murine lung tumor model. -
FIG. 10 shows no significant differences in mean spleen weights among study groups in the evaluation of the anti-tumor activity of OV/GM combination in a murine lung tumor model. -
FIG. 11 shows the synergistic anti-tumor activity of OV/GM (POV-601+PGM-001) combination in a murine lung tumor model. - The following detailed description and examples illustrate certain embodiments of the present invention. Those of skill in the art will recognize that there are numerous variations and modifications of this disclosure that are encompassed by its scope. Accordingly, the description of certain embodiments should not be deemed as limiting.
- All references cited herein, including, but not limited to, published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification.
- More than 40 oncolytic viruses (OVs) have been evaluated for their therapeutic potential in pre-clinical and clinical studies (Miest & Cattaneo, Nat Rev. Microbiol. 12(1): 23-34, 2014; Buijs et al., Hum. Vaccin. Immunother. 11(7): 1573-84, 2015; Patil et al., 1. Contemp. Dent. Pract. 16(8): i-ii, 2015; Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015). Disclosed herein are OV combination therapies containing gut commensal bacteria species. In certain embodiments, the combination therapy comprises the orf virus (ORFV) due to its documented safety profile as well as its unique ability to cause repeat infections. In addition, ORFV exhibits an ability to induce robust stimulatory immune responses with the special involvement of natural killer (NK) cells and dendritic cells (DCs), and ORFV's replicative “niche” has an extensive vasculature, similar to a tumor microenvironment, which has beneficial effects on its anti-tumor activity (Rintoul et al., Mol. Ther. 20(6): 1148-57, 2012; Rziha et al., Methods Mol. Biol. 2016; 1349:177-200, 2016). Furthermore, ORFV shows superior in vivo anti-tumor activities in immunocompetent murine lung cancer models and in human lung cancer xenograft models. In some embodiments, ORFV recombinants containing either reporter or anti-tumor enhancing genes are designed to facilitate ORFV tissue distribution and biopsy analysis and boost ORFV's antitumor activity. In another embodiment, ORFV is the main component of a combination antitumor treatment containing an augmenting agent.
- In some embodiments, in vivo ORFV monitoring is carried out by a recently developed technology (Rziha et al., Methods Mol. Biol. 2016; 1349:177-200, 2016) that rapidly detects ORFV viral load and the delayed re-emergence of its genomes in the blood. Positive readout at an extended time point after ORFV administration indicates intratumoral viral replication and subsequent leakage into the systemic circulation, suggesting a more potent anti-tumor reaction. In a preferred embodiment, the therapeutic potential of the ORFV-containing combination treatment is evaluated by analysis of tumor burdens and animal survival rate of the testing subjects. Other viral species for evaluation include, but are not limited to, species within the poxviridae family, for example, a vaccinia virus (VACV), named POV-801 in this invention.
- OV treatment alone usually exhibits low antitumor efficacy, in terms of both the population response rate and individual patient recovery, which has been observed in both in preclinical and clinical studies (Kim, Gene Ther. 8(2): 89-98, 2001; Kelly & Russell, Mol. Ther. 15(4), 651-59, 2007; Burke et al., Curr. Opin. Virol. 13:55-60, 2015; Harrington et al., Expert Rev. Anticancer Ther. 15(12): 1389-403, 2015; Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015; Patil et al., J Contemp. Dent. Pract. 16(8): i-ii, 2015; Seymour & Fisher, Br. J. Cancer 114(4): 357-61, 2016). Therefore, disclosed herein are methods of creating favorable anti-tumor immune conditions within a test subject with an agent, such as the gut commensal bacteria, to create this pre-condition. In a particular embodiment, a variety of gut commensal bacterial species are evaluated for augmenting the antitumor activity of the selected OVs. In a preferred embodiment, the gut bacteria genus is Bifidobacterium. Certain bacterial species within this genus have also been used to ameliorate clinical symptoms of irritable bowel syndrome and inflammatory and necrotizing enterocolitis (Ng et al., Inflamm. Bowel Dis. 15, 300-10, 2009; Gareau et al., Nat. Rev. Gastroenterol. Hepatol. 7, 503-14, 2010) based on its ability to modulate the balance of the gut microbiota (Etzold et al., Environ. Microbiol. 16, 888-903, 2014). The safety and benefits of Bifidobacterium in preventive medicine have been well documented, and its composition can fluctuate in the range of ˜6% to ˜-36%.
- In some embodiments, Bifidobacterium's potential augmenting effects to a selected OV are evaluated in preclinical studies. In other embodiments, in viro monitoring of Bifidobacterium is performed using a modified terminal restriction fragment length polymorphism (T-RFLP) analysis of test subject's fecal samples (Nagashima et al., Biosci. Microflora. 25: 99-107, 2006). The physiological effects of Bifdobacterium may also be evaluated using various in vitro assays. In certain embodiments, the augmenting effect of Bifidobacterium is assessed by comparing the tumor burden and survival rate of the test subjects treated with OV by itself as well as OV with Bifidobacterium. Other gut commensal bacteria species for evaluation include, but are not limited to, those published by the World Gastroenterology Organization or species discovered through the disclosed hierarchical clustering studies.
- In other embodiments, the immunomodulatory effects of herb extracts or medicines that can regulate the composition and function of the gut commensal bacteria species are tested.
- In certain embodiments, human clinical trials of successful agent-containing combination OV therapy are designed following the completion of pre-clinical studies. In a preferred embodiment, enrolled patients are unresponsive to current antitumor therapies and are potential “elite responders” based upon the disclosed hierarchical clustering analysis platform.
- In certain embodiments, the OV is administered to human subjects about one week to two months after the gut commensal bacteria are administered. In a preferred embodiment, the OV is administered to human subjects about one month after the gut commensal bacteria are administered. In mice, the oncolytic virus is administered about one to two weeks after the gut commensal bacteria are administered. In some embodiments, an effective amount of the gut microbiota is from about 109 to 1011 cfu. In still other embodiments, an effective amount of the oncolytic virus is from about 105 to 1010 pfu.
- As part of this disclosure, at least 2 tubes of orf virus comprising virus POV-601 have been deposited and made available to the public without restriction (but subject to patent rights), with the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan 430072, China. The deposit, designated as CCTCC Deposit No. V201713, was made on behalf of Minjie Hu on Mar. 28, 2017. This deposit was made and will be maintained in accordance with and under the terms of the Budapest Treaty with respect to seed deposits for the purposes of patent procedure.
- In some embodiments, the combination therapies are evaluated in human disease, particularly cancer. There are more than 200 types of human cancers (ACS (2015) Global Cancer Facts & Figures). Some cancer types contain a high degree of de novo mutations, which encode neoantigens of the clinical failure key drivers. Certain neoantigens that reside in the cells of spatially separated intratumoral subclones within a solid tumor are released out upon OV's oncolysis. The released neoantigens could be presented by a set of antigen presenting cells (APC), like the dendritic cell (DC), and a whole panel of immunity against these neoantigens will be initiated, leading to a potent eliminating action to all the existing cancer cells harboring different neoantigens. Disclosed herein are methods of increasing the efficacy of neoantigen presentation and immunity induction by pre-conditioning a host's immune system with a selected augmenting agent, generating strong systemic antitumor responses. In some embodiments, the method is used for, but not limited to, high mutation cancer types including melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, and renal cancer. Melanoma and lung cancer patients, compared to patients with other types of cancers, respond favorably to immune checkpoint inhibitors (Ipilimumab, Nivolumab, and Pembrolizumab) and to the oncolytic virus therapy T-VEC, which manifests through prolonged survival rates. In a preferred embodiment, the combination therapy is used to treat lung cancer. In other embodiments, the combination therapy is used to treat high-mutation cancer types. In still other embodiments, the combination therapy is used to treat cancer types having normal or low mutation rates.
- In some embodiments, antitumor responses are evaluated in preclinical studies using selected animal models. Various murine models that have been developed to examine responses to a developing therapy may be used herein. These experimental mouse models include, but are not limited to, models falling within three main categories: transplantable tumors, genetically engineered/transgenic models, and humanized mouse xenograft models. Transplantable tumor models are the most widely used in cancer preclinical studies due to rapid output. On the other hand, transgenic models confer greater phenotypic variability, and xenograft experiments are usually performed in either nude or severe combined immunodeficiency (SCID) mice that are deficient in adaptive immunity. In certain embodiments, pre-clinical evaluation of the disclosed combination therapies are evaluated in multiple tumor models. In other embodiments, transplantable models are designed to observe the adaptive immune response. In these models, mouse strains have the identical genetic backgrounds to that of the transplanted cancer cell lines. An example of this transplantable model is C57BL6 house mice challenged intravenously with a murine B16-F10 melanoma cancer cell line to create a lung metastasis cancer model whose adaptive immune response can be monitored. In certain embodiments, the tumor-bearing animals of the transplantable model studies are administered with or without the selected augmenting agent, followed by application of the testing OV, and harvesting and processing their lungs for tumor burden analysis, as shown in
FIG. 11 this invention. In other embodiments, a fluorescently labeled human lung cancer cell line, including but not limited to A549, is engrafted subcutaneously into the flank of a nude mouse strain, including but not limited to CD1, to create a human lung cancer xenograft model. In certain embodiments, the murine B16-F10 melanoma cell line was subcutaneously injected into the right flank of a C57BL/6 mouse, and tumor volumes are measured using digital calipers following administration of the augmenting agent and the testing OV, as shown inFIGS. 6,7,8 . In certain embodiments, the augmenting immune responses are initially assessed by counting total numbers of splenic NK, DC, and CD8 T cells or by analyzing the expression levels of certain lymphocyte activation markers (e.g. CD69, CD80 and CD 86) and immune responding cytokines (e.g. interleukin-1β (IL-1β), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2, IL-6, TNF-α and IFN-α) before and after agent administration. In some embodiments, the tumor burden and animal survival analysis are assessed. In other embodiments, preclinical tumor models for other types of cancers are created and used to evaluate the disclosed combination therapies. Data generated from the preclinical studies provide useful safety and efficacy information about the disclosed combination therapies and guide the design of human clinical trials. - All selected augmenting agents and oncolytic viruses are formulated following Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) guidelines. In certain embodiments, the augmenting bacterial agents are obtained from a commercial resource or human fecal samples. In some embodiments, commercially obtained bacteria in live forms are expanded on reduced clostridial medium (RCM) agar in anaerobic conditions. The bacteria obtained may be formulated in phosphate-buffered saline (PBS) at 5×106 c.f.u/μl, Before OV application, a starting dose of 200 μl formulated bacteria is administrated to each mouse through oral feeding based on published data (Sivan et al., Science 350(6264): 1084-89, 2015). The total amount of formulated bacteria is given either in a single dose or in multiple doses spread out over several days (e.g. 14 days), and the frequency and duration of dose administration is determined.
- The oncolytic viruses are formulated either in PBS with 10% v/v glycerol or in 30 mM Tris with 10% (w/v) sucrose at a viral concentration of 105 p.f.u/μl. Although the accurate dosage of an OV is dependent on its virulence and the nature of the targeting tumor, an initial dose of 107 p.f.u. is administered to each mouse based on published data (Rintoul et al., Mol. Ther. 20(6): 1148-57, 2012). The viral formulation is administered either locally or systemically, depending on the animal model. Since the first OV drug T-Vec was successfully delivered through local injection (Harrington et al., Expert Rev. Anticancer Ther. 15(12): 1389-403, 2015), the same approach can be used in this invention. In certain embodiments, up to five doses of 100 μl viral formulation are injected intratumorally at different time points, and the treated tumors are measured 2-3 times per week using digital calipers. Systemic delivery has the benefit of evaluating adaptive immune response, which is critical for treating a metastatic tumor. In other embodiments, mice are treated intravenously with five doses of 100 ul viral formulation and are monitored for signs of organ distress. To aid in administration in clinical studies, the selected bacterial agent(s) and the chosen oncolytic virus(es) may be formulated as an ingredient in a pharmaceutical composition separately. Therefore, in some instances, the compositions may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives and various compatible carriers. The proportion and identity of the pharmaceutically acceptable diluent depends on the chosen route of administration, compatibility with a live virus and, where applicable, compatibility with the stability of the immune-augmenting agent. Starting doses of 3×107 c.f.u. kg−1 of the selected bacterial agent and 1×107 p.f.u. kg−1 of the chosen virus in formulated forms are used based on published clinical studies (Kaufman et al., Nat. Rev. Drug Discov. 14(9): 642-62, 2015; Waller et al., Scand. J. Gastroenterol. 46: 1057-64, 2011). For systemic delivery studies, the formulated virus is diluted in bicarbonate-buffered saline in a total infusion volume of 50 ml immediately before intravenous infusion, and is infused over the course of 60 min. Tumor response is assessed by contrast-enhanced computed tomography (CT) imaging, maximum tumor diameters, and Hounsfield units (Breitbach et al., Nature 477, 99-102, 2011).
- The current invention also aims to build a platform for the selection of elite responders to individual OV therapy. In certain embodiments, fecal samples are collected from a group of 60 consented subjects divided into three categories: cancer patients, non-disease subjects in a high-risk population, and healthy subjects in a low-risk population. The microbial DNA in each sample is purified with methods modified from the protocol of American Human Microbiome Project (HMP) (Wesolowska-Andersen et al., Microbiome, 2, 19, 2014). Following DNA purification, the quality of the DNA is checked with a spectrophotometer, and only DNA with a 260 nm/280 nm ratio higher than 1.8 is subject to 16S ribosomal RNA target sequencing or metagenomic sequencing.
- PCR amplification of the 16S RNA gene is conducted with primers designed based on the conserved regions across all bacterial strains, and the PCR products are purified with the QiaQuick PCR purification kit from, but not limited to, Qiagen. In certain embodiments, the PCR-amplified 16S ribosomal RNA (rRNA) target sequencing is performed. In other embodiments, the abundance of species-specific sequences of the variable regions of rRNA is utilized for clustering analysis. In comparison to 16S rRNA sequencing, metagonomic sequences enable exploration of thousands of species. In some embodiments, reads from metagenomic sequencing are mapped to the strain-specific sequences from the bacterial genome databases built from 3000 reference genomes (Grice & Segre, Annu. Rev Genomics Hum. Genet., 13, 151-70, 2012; Human Microbiome Jumpstart Reference Strains et al., 2010). The reference genomes are indexed with a Burrows-Wheeler index. The mapped data are normalized based on the length of reference sequences and total read counts. The calculated abundances of bacterial strains are further subjected to clustering analysis.
- In certain embodiments, the bioinformatics tools developed by R statistic programming are used to generate a taxonomic tree (Segata et al., Nat. Methods, 9(8); 811-14, 2012) and an enterotype cluster for each person. In other embodiments, tumor-bearing mice are individually pre-treated with each collected human fecal sample, followed by a treatment with a chosen OV (e.g. ORFV). The tumor burden and animal survival rate in each testing mouse are monitored and analyzed to generate a set of anti-tumor efficacy data. Following a comparison analysis of all the “positive” taxonomic trees and enterotype clusters from persons having the positive antitumor efficacy data and certain mathematic calculations, one platform is built for selection of potential elite responders to the chosen OV. In other embodiments, the number of human participants is increased to build similar platforms for other OV therapies. In some embodiments, new gut commensal bacteria species may be identified during the comparison analysis. According to this disclosure, the elite responder selection platform can facilitate the development of personalized precision medicine.
- “Gut microbiota,” “gut commensal bacteria,” “gut microbes.” or “GM” refer to an ensemble of microorganisms that reside in various organs, preferably the intestines and/or stomach. Gut microbiota contain tens of trillions of microorganisms. In some embodiments, gut microbiota are common to most individuals, while in other embodiments, gut microbiota are specific to an individual.
- The phrase “anticancer activity” or “antitumor activity” refers to the ability of an agent to kill cancer cells, decrease the severity of the cancer, or block or prevent the cancer from spreading.
- An “effective amount” of an oncolytic virus is meant as an amount sufficient, upon single or multiple dose administration, to treat a cancer cell, prolong or prevent advancement of the cancer (e.g. prevent additional tumor growth of a cancer, prevent additional inflammatory response), ameliorate, alleviate, relieve, or improve a subject's symptoms of the cancer beyond that expected in the absence of such treatment. The amount of oncolytic virus required may depend on the particular virus given, the type of cancer being treated, the route of administration, and the length of time required to treat the cancer. It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the oncolytic virus, the age, body weight, general health, sex, diet of the patient, time of administration, rate of excretion, drug combinations, the judgment of the treating physician, and the severity of the particular cancer being treated. In certain aspects where the oncolytic virus is administered in combination with gut microbiota, the amount of additional oncolytic virus present in a composition of this invention typically will be no more than the amount that would normally be administered in a composition comprising that oncolytic virus as the only active agent.
- “Pre-condition” refers to a process of administrating a set of gut microbes to test subjects ahead of OV treatment. The intake of gut microbes interrupts the subjects immunological equilibrium that pathologically favors tumor progression. The gut microbes also enhance the subject's immune system to recognize tumor-specific signals released from OV-targeted cells. A systematic immunological response to tumor loci is boosted after administration of gut microbes.
- The term “intratumoral” refers to the space within a tumor. The mechanism of pre-conditioning is critical for an effective antitumor response. In certain embodiments, a “pre-conditioned” state facilitates the killing of metastatic cancer cells at distant sites previously unseen by a virus and intratumoral bystanders localized outside of the infected area.
- An “effective amount” of a gut microbiota is an amount sufficient to create the “pre-condition,” and thus facilitates an effective antitumor response.
- The following examples are intended to be illustrative and in no way limit the scope of the disclosure.
- A. Isolation of the Microbial Strains
- Isolation and Purification of Prajma's Microbial Strains
- A specific bacterial strain is purified by separation of a single bacterial colony from the bacterial culture. A starting probiotic material containing several bacterial strains was cultured with serial dilutions on solid agar culture plates. These plates contained well-separated colonies, from which single colonies were picked up, each representing individual strains. Each picked colony was streaked onto fresh plates and incubated for 24-72 hours (strain-dependent) at 37° C. to allow the formation of a new individual colony. The process was repeated multiple times to ensure that the bacteria within a colony originated from a single clone. The final colonies were used to expand the selected bacterial strains.
- B. Microbial culture
- Equipment Set Up and Configuration
- To begin an anaerobic culture, the culture chambers of a Work Station were filled with mixed gases. The components of the mixed gases are nitrogen (80-90%), carbon dioxide (5-10%) and hydrogen (5-10%). The catalyst palladium (Pd) was used to remove the trace oxygen by enabling a reaction between oxygen and hydrogen.
- Preparation of a De-Gas Broth
- An autoclaved culture broth was continuously flushed by filtered nitrogen gas for 30-60 minutes until the color of the oxygen indicator (0.3% resazurin) changed from pink to colorless. The de-gassed broth bottle was then capped and sealed with parafilm to prevent air leakage. All the broths were used within the culture chamber of a Work Station.
- Strain Stocks Preparation
- 14 ml bacterial culture from individually selected colonies was mixed with 14 ml of 30% glycerol in water, and aliquoted into 2 ml stocks. The stocks were kept at −80° C.
- C. Expansion of the Selected Strains and Test of Microbial Growth
- 100 μl of a strain stock was inoculated into a 50 ml centrifuge tube containing 50 ml of a liquid culture broth, followed by incubation at 3?° C. between 24-72 hours (strain-dependent). The 50 ml culture was then transferred into a 1 liter glass bottle containing 1000 ml of liquid culture broth, and allowed to continue growth at 37° C. between 24-72 hours. The growth property of each selected strain was evaluated by performing growth curve experiments. 3 ml sample was taken from a 50 ml tube containing 50 ml bacterial culture at sequential time points, and OD (optical density) value at 600 nm was measured by a plate reader. A growth curve for each strain was plotted (OD read vs. time) and the log growth phase for each strain was determined. The log phase culture of each strain was used for the preparation of animal administration solutions.
- D. Quantification of the Selected Microbial Strains
- To quantify the titer of a selected bacterial strain, a serial dilution culture was set up. A glycerol stock of a bacterial strain was serially diluted to the concentrations of 10×, 102×, 103×, 104×, 105×, 105×, 106×. The diluted bacteria were cultured on solid agar plates. The number of the colonies on each plate was counted and the titer of original bacterial stock was calculated by multiplying the count and dilution factor.
- E. Preparation of the Bacteria Administration Solutions for Animal Studies
- PGM-001
- 2 ml of sterile PBS was added to a 50 ml centrifuge tube containing one capsule (440 mg/capsule) of a probiotic powder and stirred for 6 minutes with a sterile glass stick to re-suspend the powder. The suspension was then centrifuged at 500 rpm for 2 minutes to let the wall-adhered suspensions down to the tube bottom, which is the PGM-001 administration solution with a cfu at 5×109/ml.
- All the tubes containing individual administration solution were filled with nitrogen gas and kept at room temperature less than 60 minutes before animal administration.
- F. Molecular Detection and Speciation of Microbial Species
- Detection of Bacterial Strains with PCR and 16S Sanger DNA Sequencing
- The genomic sequences from different species can provide distinguishing signatures for species differentiation. The 16S rRNA gene sequence can fulfill the task with integrative homologous and clustering analysis of its hypervariable regions (V1-V9). The 16S rRNA gene was amplified by the polymerase chain reaction (PCR) with the primers: 5CGG GGG TGC TGC CCA CTT TCA TG3′ and 5′GCT TGT TGG TGA GGT AAC GGC T3′. The PCR product then underwent Sanger sequencing. The sequences started from both ends were processed for assembly of the 16S rRNA gene. The sequences were compared to the microbial genome databases from the NCBI (National Center of Biotechnology Information at National Institute of Health) with the Blastn computational program, and the species with high sequence identity and homology (>99%) to the query sequences in the hyper-variable regions were identified.
- qPCR: Primer and Experiment Design
- qPCR is used as a pre-condition screening with an identified panel of strain specific primers. The quantification of the abundance of rRNA genes in feces could infer the bacterial composition in the gastrointestinal tract. The PCR amplification curve for the panel of bacterial species is utilized for the evaluation of the species composition in the feces. The composition is used to classify the subtypes of tumor bearers.
- Genomic DNA is extracted from samples using the Mo Bio Powersoil®-htp 96 Well Soil DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, Calif.) or the QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, Calif.). The thermo-cycling conditions are set as follows: 95° C. for 2 minutes followed by 45 cycles of 95° C. for 3 seconds, 60° C. for 30 seconds, and subsequent measurement of FAM channel fluorescent readings.
- G. Microbial 16S rRNA Gene Sequencing and the Bioinformatics Analysis of the High Throughput Datasets
- The hyper-variable regions (V3, V4 and V5) of the microbial 16S rRNA gene contain unique strain-specific sequences that can be utilized for studying the microbial lineages. With integrative bioinformatics analysis, phylogeny and taxonomy of the gut microbial species can be elucidated.
- The microbial genomic DNA was purified from fecal pellets collected from experimental mice and subject to the high throughput 16S ribosomal RNA (rRNA) gene sequencing by the Illumina sequencing platform. Below is a description of the sequencing data processing.
- Selection of Samples for the 16S a Gene Sequencing
- The fecal samples from the tumor bearing mice were collected for the bacterial DNA purification. In order to evaluate the effect of gut microbial abundance on the treatment of the tumor, the fecal samples were collected from normal untreated mice as controls, microbial treated, and oncolytic virus treated mice. The fecal samples for each mouse are selected at three time points: before microbial administration, before B16 inoculation, and two weeks after the B16 inoculation. The DNAs were then assessed for the quality control and concentration measurement. Samples passed the quality control are subject to the 16S rRNA gene sequencing downstream.
- 16S rRNA Gene Sequencing, Data Transfer, and Storage
- The hyper-variable regions of 16S rRNA genes were amplified using the following primers:
-
Primer Type Region Name Primer (5′→3′) Bacterial V4 515F GTGCCAGCMGCCGCGGTAA 16S V3 + V4 806R GGACTACHVGGGTWTCTAAT 341F CCTAYGGGRBGCASCAG 806R GGACTACNNGGGTATCTAAT V4 + V5 515F GTOCCAGCMGCCGCGGTAA 907R CCGTCAATTCCTTTGAGTTT - Sequencing platform generated the reads with 250 bp paired-end (PE) with an average of 10,000 reads per sample. The gz-compressed data gzip were transferred through the ftp (file transfer protocol) server.
- Raw Data Processing
- The sequencing raw reads were pre-processed by demultiplex step of reads, clip step of barcodes, primers and adaptor clips, joining step of paired-end reads. The fastq format was generated for raw reads and pre-processed.
- Sequencing Reads QC
- The quality control tool, FastQC, is used to assess the sequence files to report base sequence quality, GC content, N base level, sequence duplication level, sequence overrepresentation level, and Kmer content.
- Analysis of OTU (Operational Taxonomic Unit) Taxonomy
- The pre-processed sequence reads were subjected to the QIIME pipeline for clustering. The sequence reads as input into the pipeline under sequence similarity comparison were then classified into OTUs (Operational Taxonomic Units) with the Greengenes database. With sequence alignment data to the Greengenes references, the abundance of the taxonomic units is evaluated. By comparing the differential abundance between samples with different microbial treatments for the tumor progression, the correlation of the OTU and efficiency of each treatment are identified.
- A. Adenocarcinomic Human Alveolar Basal Epithelial Cell Line A549 Culture
- Thaw A49 Cells
- A549 Cells (Prajna code: Cl; originally obtained from BeNa Culture Collection, Cat #BNCC337696) are thawed by transferring a frozen vial containing 2×106 cells/ml from a liquid nitrogen tank into a 37° C. water bath. Cell culture medium (10% FBS in DMEM) is warmed in a 37° C. water bath. The vial surface is thoroughly wiped with 75% alcohol. The vial is opened in a cell culture hood and transferred into a 1.5 ml sterile tube with a P1000 pipet. 10 ml of the pre-warmed cell culture medium is slowly added and centrifuged at 230×g for 5 min at room temperature (RT). The supernatant is decanted and the cells are re-suspended in the cell culture medium. The cells are seeded into a 75 cm2 flask at a cell density of 0.7-2×106/flask and placed into a 37° C. cell culture incubator to allow cell growth. The medium is changed the next day.
- Subculture of A549 Cells
- The cultured cells are viewed under an inverted microscope and the cell confluency is assessed; if the cell confluence is between 50-80%. the next steps are proceeded with. The medium is aspirated and the cell monolayer is rinsed with 10 ml DPBS (without Ca2+/Mg2+). 5 ml of 0.25% trypsin/EDTA is added into the rinsed flask. The flask is rotated to make sure that the added trypsin/EDTA covers the cell monolayer. The flask is placed in the incubator for 4-6 minutes. The cells are examined under an inverted microscope to ensure that all the cells are detached and floating. 10 ml of the fresh cell culture medium is added to inactivate the trypsin. The cells are re-suspended with a 10 ml pipet. The cell suspension is transferred into a 50 ml conical tube and the cells are centrifuged at 230×g for 5 min at RT. The supernatant is decanted and the cells are re-suspended in about 5 ml of the cell culture medium. A small aliquot of cells (100-200 μl) is removed and the cells are counted with a Life's cell counter. The cell density is adjusted to 1×106 cells/ml with the cell culture medium. The re-suspended cells are seeded into T175 flasks at a cell density of 2×106/flask. The flask is placed into a 37° C. cell culture incubator to allow cell growth, and the medium is changed every other day. The subculture process is repeated as needed.
- Cryopreservation of A549 Cells
- The cultured cells are viewed under an inverted microscope to make sure that the cell confluence is close to 80%. The A549 cells are harvested and re-suspended with trypsin/EDTA using the steps described above in “Subculture of A549 cells,” A small aliquot of cells (100-200 μl) is removed and the cells are counted with a Life's cell counter. The cell viability is examined during cell counting (ideally, the cell viability should be in excess of 90% in order to achieve a good recovery after freezing). The cells are centrifuged at 230×g for 5 min at RT and re-suspended at a density of 1×106 cells per ml in the cell freeze medium. The cell suspension is aliquoted into 1 ml aliquots in 2 ml cryogenic vials and the vials are placed into a −80° C. freezer for 4 hours. The vials are transferred to the gas phase of a liquid nitrogen storage tank and the location of each vial is recorded.
- B. Viral Production
- Infection of Virus
- Virus infection is performed with Prajna code: POV-801, originally obtained from China Center for Type Culture Collection, Cat # GDV117. The cultured A549 cells in a 175 cm2 flask are viewed under an inverted microscope to make sure that the cells have reached confluence. The medium is changed and 200 μl of a viral stock is transferred into the flask. The flask is rotated to ensure that the added viral solution completely covers the cell monolayer. The flask is placed into a 37° C. cell culture incubator to allow viral infection of A549 cells. The viral treated cells are examined every day under an inverted microscope. If over 90% of the cells changed their morphology from a flat to round shape, the infection process is complete.
- Cryopreservation of Virus
- Infected A549 cells are viewed under an inverted microscope to ensure that the infection process is complete. The culture medium is transferred into a 50 nil conical tube and washed with DPBS. 3 ml 0.25% trypsin/EDTA are added and the flask is placed into a 37° C. incubator for 3 minutes. A small volume of fresh cell culture medium is added to inactivate the trypsin. The cells are centrifuged at 3000 rpm for 10 min at RT and the supernatant is aspirated. The pellet is re-suspended with 10 mM EDTA in PBS and the viral stocks are stored at −80° C.
- Viral Release from the Infected Cells
- The freezing and thawing of the viral stock is repeated three times. The treated viral samples are sonicated for 3×1 minutes. The sonicated samples are centrifuged at 230×g for 10 min at 4° C. The supernatant is transferred into a 15 ml tube and the remaining pellet is re-suspended with PBS. The supernatant and suspension are placed into a −80° C. freezer.
- Preparation of the Cells for Viral Titer Determination
- Cell medium is aspirated from an A549 confluent T175 flask. The cell monolayer is rinsed with 10 ml DPBS (without Ca2+/Mg2+). 5 ml of 0.25% trypsin/EDTA are added into the rinsed flask and the flasked is rotated to ensure that the added trypsin/EDTA covers the cell monolayer. The flask is placed in the incubator for 4-6 minutes. The cells are examined under an inverted microscope to ensure that all the cells are detached and floating. 5 ml of fresh cell culture medium is added to inactivate the trypsin. The cells are re-suspended with a 10 ml pipet. The cell suspension is transferred into a 50 ml conical tube. The cells are centrifuged at 230×g for 5 min at RT and the cells are re-suspended in 5 ml of the cell culture medium. A small aliquot of cells (100-200 μl) is removed and the cells are counted with a Life's cell counter. The cell density is adjusted to 1×106 cells/ml with the cell culture medium. The cell suspension is diluted into 1×105 cells/ml with the cell culture medium. 2 ml of the cell suspension is transferred into each well of a 6-well plate and the plate is swirled to ensure the even distribution of cells in each well. The cells are cultured in a 37° C. incubator for 2 days.
- Viral Titer Determination
- A stock of the virus to be tittered is thawed on ice. A serial dilution of 102, 103, 104, . . . 108 is prepared. Each well of the cell-seeded 6-well plate is labeled with the corresponding dilution. The medium is aspirated from each well. a ml of the viral dilution is transferred into its corresponding well and the plate is incubated in a 37° C. incubator for 60 minutes. The viral inoculum is removed from each well. 2 ml of a freshly made culture medium (2% FBS in DMEM) is added to each well and the plate is incubated in a 37° C. incubator for 2 days. Following the 2-day incubation, 2 ml of a crystal violet solution is added to each well. The dye is allowed to sit on the cells for 10 minutes. The plaque numbers in each well are counted. The following equation is used to calculate the plaque formation unit (pfu):
-
(# of plaques counted)/(mL of inoculum/well)×dilution factor=pfu/ml - To evaluate the inhibitory functionality of gut microbiota on tumor growth, an assay was developed that showed high bifidobacteriaceae abundance correlated with slower tumor progression. C57BL/6 mice were separated into two groups: T0: No antibiotic treated and T1: antibiotic treated. The mice in both groups had been housed in our SPF facility for 4 days and treated with or without antibiotics for two weeks before 10E6 B16-F10 cells were inoculated subcutaneously. Tumors were measured every day starting from the 10th day after the inoculation. Fecal pellets were collected at two weeks after the B16 inoculation. Data show that tumors generally grow faster on the T1 mice than on most of T0 mice (
FIG. 1 ). This suggests that ablation of gut microbes enhances tumor growth and further implies microbes suppress tumor progression. - High throughput 16S rRNA gene sequencing was utilized to evaluate the different microbe genus. The microbial genomic DNA was purified from the fecal DNA. The sequencing reads were processed and mapped to the Greengenes databases. The 16S rRNA gene abundances of each microbial genus were evaluated. Further differential abundance was analyzed by using R program DESeq. The normalized read counts were utilized to plot a heatmap with hierarchical clustering method (
FIG. 2 ).FIG. 2 shows that two samples displayed low levels of bifidobacteriaceae (A9 and A23) in the untreated group T0. The analysis was performed with blinded sample labeling. - With this information on tumor growth, samples A9 and A23 matched the two mice with exceptional tumor growth (
FIG. 3 ). The experiment revealed that the bifidobacteriaceae played a role in tumor suppression. - A. Experimental Design
- The experimental design is summarized in Table 1:
-
TABLE 1 Oncolytic Administration Group # Animals # Virus Route Dose 1 3 POV-601 Subcutaneous 4 X of the dose used in the anti-tumor study 2 3 POV-601 Intravenous 4 X of the dose used in the anti-tumor study 3 3 POV-801 Subcutaneous 4 X of the dose used in the anti-tumor study - B. Procedure and Evaluation
- Test Articles and Animals
- Test articles include Oncolytic Virus (OV): POV-601: 1×108 PFU/mL; POV-801: 1×108 PFU/mL. POV-601 is from CCTCC Deposit No. V201713. POV-801 was obtained from China Center for Type Culture Collection (Wuhan, China, Cat #GDV117). C57BL/6 female mice, aged between 49-62 days. were supplied from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in a standardized animal facility following the Animal Care and Veterinary Services standard operating procedures.
- Procedure
- A test article was injected into a testing animal either subcutaneously or intravenously at a dose shown in Table 1. Each testing mouse was weighed and the weight was recorded every day until all the testing mice were sacrificed. The mortality, behavior, and body weight were evaluated everyday.
- Results
- No mice died after virus injection during the test. An electronic balance (supplied from Mettler, Model: ML1602T) was used to measure the body weight one day before the OV was injected, followed daily. No significant differences in mean body weights were observed among the study groups. No groups had an unintentional decline in body weight more than 5%, therefore, the result of the toxicity tests showed that the viruses had no toxicity to the host (
FIGS. 4A-C ). - A. Experimental Design
- The experimental design is summarized in Table 2:
-
TABLE 2 Control or Control or Group Animals * GM administration OV Injection Control 15 PBS: one day before B16-F10 PBS: the first injection was performed injection, followed by weekly based on the tumor volume followed at administration, amounting to 4 a 72 hour interval, amounting to 4 times times PGM-001 15 PGM-001: one day before B16- PBS: the first injection was performed only F10 injection, followed by weekly based on the tumor volume followed at administration, amounting to 4 a 72 hour interval, amounting to 4 times times POV-601 15 PBS: one day before B16-F10 POY-601: the first injection was only injection, followed by weekly performed based on the tumor volume administration, amounting to 4 followed at a 72 hour interval, times amounting to 4 times POV-801 15 PBS: one day before B16-F10 POV-801: the first injection was only injection, followed by weekly performed based on the tumor volume administration, amounting to 4 followed at a 72 hour interval, times amounting to 4 times POV-601 + 15 PGM-001: one day before B16- POV-601: the first injection was PGM-001 F10 injection, followed by weekly performed based on the tumor volume administration, amounting to 4; followed at a 72 hour interval, times amounting to 4 times POV-801 + 15 PGM-001: one day before B16- POV-801: the first injection was PGM-001 F10 injection, followed by weekly performed based on the tumor volume administration, amounting to 4 followed at a 72 hour interval, times amounting to 4 times - B. Procedure
- Test and Control Articles
- Test—
-
- Oncolytic Virus (OV): POV-601: 1×108 PFU/mL; POV-801: 1×108 PFU/mI.
- Gut Microbio (GM): PGM-001: 1×109 CFU/mL
- Control—Phosphate Buffered Saline
- POV-601 is from CCTCC Deposit No. V201713. POV-801 was obtained from China Center for Type Culture Collection (Wuhan, China, Cat #GDV117). PGM-001 was obtained from Seeking Health (Bellingham, Wash., USA, SKU: PBIFIDO-60-CAPS).
- C. Animal Model and Assays
- Animals
- C57BL/6 female mice, aged between 49-62 days, were supplied from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in a standardized animal facility following the Animal Care and Veterinary Services standard operating procedures.
- Anti-Tumor Activity Tests in a Murine Subcutaneous Melanoma Tumor Model
- GM was formulated at a density according to the Test and Control Articles, and 200 μl of GM was orally administrated into each testing animal one day before the B16-F10 cell injection, followed by the schedule listed in Table 2. To establish a subcutaneous melanoma model, murine B16-F10 melanoma cells harvested from an adherent culture were formulated in PBS at a density of 2×106/cells, 100 μl of the formulated cells were injected subcutaneously into the right flank of each testing mouse on
day 0; and subcutaneous tumors were allowed to grow. Once the group mean tumor volumes reached approximately 20-40 mm3 (about 8-10 days post-injection), each tumor site was injected with 20 μl of either the control (PBS) or the testing OV (POV-601 or POV-801) at a density according to the Test and Control Articles, followed by additional injections at certain time points scheduled in Table 2. All the testing animals were euthanized atday 24 after B16-F10 injection. Those animals whose tumor volume was over 3500 mm3 were sacrificed before the euthanasia day. - Evaluations
- Animals dead before their scheduled sacrifice day were discarded without evaluation. Clinical observations were performed everyday to assess mortality. Behavioral observations were performed everyday. Body weight measurement was performed 24 hours following each OV injection. The tumor volume was measured daily using a caliper, and calculated by the formula Tumor volume=L×W2/2.
- Data Analysis
- All the collected data (tumor size, body weight, and spleen weight) were analyzed with Excel. The anti-tumor effects were compared among all the different testing groups.
- D. Results
- Clinical Everyday Observations
- For the control group, 6 animals were dead on
day 15/16/21/22/23; for the POV-801 only group, two animals were found dead on theday 20/22; for the POV-801+PGM-001 group, one animal was found dead on theday 21. No macroscopic lesions were observed for any of the animals. - Body Weight
- Body weight was measured once before OV-injection and four times after each OV-injection. amounting to five times during the experiments. There were no significant differences in mean body weights among study groups (
FIG. 5 ). - POV-801+PGM-001 Anti-Tumor Effect and Analysis
-
FIG. 6 shows the anti-tumor activity of OV/GM combination in a syngeneic murine melanoma tumor model (Total Mice #: Control: 9; POV-801 only: 13; POV-801-PGM-001:14, Mean±SE). PGM-001 as a pre-condition was orally administrated into the groups PGM-001 only and POV-801+PGM-001 the day before the B16-F10 cells injection, B16-F10 injected into each testing animal on theday 0. Tumor-bearing animals were then treated four times subcutaneously (s.c.) with phosphate-buffered saline (PBS) as a control, or treated four times s.c. with POV-801 only, or treated four times s.c. with POV-801 and four times PGM-001 (orally administrated). Tumor volumes were measured onday 10, using a caliper (supplied from Stanley. model: 36-111), followed daily. OV was injected onDay 11. followed at a 72 hour interval (atday day 24 after B16-F10 injection. During the test, a dead animal before its scheduled sacrifice day was discarded without evaluation (FIG. 6 ). The tumor volume from different groups were compared and calculated by the formula tumor volume=L×W2/2. Bars represent the mean for each group. - POV-601+PGM-001 Anti-Tumor Effect and Analysis
-
FIG. 7 shows the anti-tumor activity of OV/GM combination in a syngeneic murine melanoma tumor model (Total Mice #: Control: 9; POV-601 only: 13; POV-601+PGM-001:13, Mean±SE). PGM-001 as a pre-condition was orally administrated into the groups PGM-001 only and POV-601+PGM-001 the day before the B16-F10 cells injection, B16-F10-F10 injected into each testing animal on theday 0. Tumor-bearing animals were then treated four times s.c. with phosphate-buffered saline (PBS) as a control, or treated four times s.c. with POV-601 only, or treated four times s.c with POV-601 and four times PGM-001. The tumor volumes were measured onday 10, using a caliper (supplied from Stanley, model: 36-111), followed daily. OV was injected onday 11, followed at a 72 hour interval (atday FIG. 7 ). Animals were euthanized atday 24 after B16-F10 injection. The tumor volumes from different groups were compared and calculated by the formula tumor volume=L×W2/2. Bars represent the mean for each group. - Anti-Tumor Effect
- The tumor volume ratios from different groups were compared and calculated by the formula=[mean value (Control Group)−mean value (Test Group)]/mean value (Control Group)×100%. The tumor volume data was collected on
day 24. The anti-tumor effects are shown inFIG. 8 and Table 3 below. -
TABLE 3 Anti-Tumor Effect = [Mean Value(Control Group) − Mean Value(Test Group)]/ Mean Value(Control Group)* 100% Group Tumor Volume Ratio Control 1012.07 / POV-601 only 1060.93 −4.83 POV-801 only 522.40 48.38 POV-601 + PGM-001 269.86 73.34 POV-801 + PGM-001 197.38 80.50 - A. Experimental Design
- The experimental design is summarized in Table 4:
-
TABLE 4 Group Animals # Control or GM administration Control or OV Injection Control 6 PBS: two times for a week before PBS: the first injection was 24 hour B16 injection, followed by weekly after B16 injection, followed at a 48 administration, amounting to 5 hour interval, amounting to 4 times times PGM-001 5 PGM-001: two times for a week PBS: the first injection was 24 hour only before B16 injection, followed by after B16 injection, followed at a 48 weekly administration, amounting hour interval, amounting to 4 times to 5 times POV-601 5 PBS: two times for a week before POV-601: the first injection was 24 only B16 injection, followed by weekly hour after B16 injection, followed at a administration, amounting to 5 48 hour interval, amounting to 4 times times POV-601 + 5 PGM-001: two times for a week POV-601: the first injection was 24 PGM-001 before B16 injection, followed by hour after B16 injection, followed at a weekly admins stration, amounting 48 hour interval, amounting to 4 times to 5 times - B. Procedure
- Test and Control Articles
- Test—
-
- Oncolytic Virus (OV): POV-601: 1×108 PFU/mL
- Gut Microbio (GM): PGM-001: 1×109 CFU/mL
- Control—Phosphate Buffered Saline POV-601 is from CCTCC Deposit No. V201713. POV-801 was obtained from China Center for Type Culture Collection (Wuhan, China, Cat #GDV117). PGM-001 was obtained from Seeking Health (Bellingham, Wash., USA, SKU: PBIFIDO-60-CAPS).
- C. Animal Model and Assays
- Animals
- C5713L/6 female mice, aged between 49-62 days, were supplied from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in a standardized animal facility following the Animal Care and Veterinary Services standard operating procedures.
- Anti-Tumor Activity Tests in a Murine Lung Tumor Model
- GM was formulated at a density, and 200 ul of GM was orally administrated into each testing animal two times for a week before the B16-F10 cell injection, followed by the schedule listed in Table 4. To establish a lung tumor model, murine B16-F10 melanoma cells harvested from an adherent culture were formulated in PBS at a density of 3×106/cells, and 100 μl of the formulated cells were injected intravenously into each testing mouse on
day 0. Lungs were excised and surface metastases were counted onday Day 1, each testing animal was injected with 100 μl of control (PBS) or the testing OV (POV-601) at the titers shown in the Test and Control Articles section, followed by additional injections at certain time points scheduled in Table 4. OnDay 10, one mice from the control group were euthanized, and its lung was harvested and examined for tumor formation. In the case that there were few tumors formed on the lung surface, all the testing animals would be euthanized onDay 14. - Evaluations
- Animals dead before their scheduled sacrifice day were discarded without evaluation. Clinical observations were performed everyday to assess mortality. Behavioral observations were performed everyday. Body weight measurement was performed twice (days −9 and o) before the first OV injection and five times on
days - Data Analysis
- All the collected data (lung metastases, body weight, and spleen weight) were analyzed with Excel. The anti-tumor effects were compared among all the different testing groups.
- D. Results
- Clinical Everyday Observation
- For the control group, one animal was euthanized on the
day 10 to evaluate tumor formation. No enough tumor spots were observed, and therefore all the testing animals were allowed to continually be housed until euthanized atday 14. - Body Weight
- Body weight was measured twice (days −9 and 0) before OV-injection and five times on
days FIG. 9 ). - Mice from all groups were euthanized at
day 14 after the B16-F10 injection. Through dissection, the spleens of all mice were removed and measured respectively (in grams). No significant differences in mean spleen weights among study groups were observed (FIG. 10 ). - POV-601+PGM-001 Anti-Tumor Effect
- Mice from all groups were euthanized at
day 14 after the B16-F10 injection, and lungs were harvested and put into cold PBS to count lung metastasis. The amount of black tumor spots on the lung surface for each mouse was counted with the naked eye. During the test, an animal in the control group was sacrificed atday 10, and the data from this animal was not included in the analyzed data inFIG. 11 .FIG. 11 shows the results of the control, PGM-001 only, POV-601 only, and POV-601+-PGM-001 treatment groups.
Claims (19)
1-21. (canceled)
22. A method of treating cancer comprising:
orally administering to a subject an effective amount of about 109 to 1011 cfu of gut microbiota of the genus Bifidobacterium; and
from about one week to two months after the gut microbiota are administered, intravenously or intratumorally administering to the subject an effective amount of about 105 to 1010 pfu of an oncolytic ORF virus having anticancer activity and that selectively targets tumor cells;
wherein the gut microbiota pre-conditions the subject's immune system to antitumor responses and augments the anticancer activity of the oncolytic ORF virus.
23. The method according to claim 22 , wherein the cancer is a type of cancer having a high degree of de novo mutations.
24. The method according to claim 22 , wherein the cancer is melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, or renal cancer.
25. The method according to claim 22 , wherein the oncolytic ORF virus is administered about one month after the gut microbiota is administered.
26. The method according to claim 22 , wherein the subject is a mammal.
27. The method according to claim 22 , wherein the subject is a human.
28. A method for augmenting the anticancer activity of an oncolytic ORF virus, comprising:
orally administering to a subject an effective amount of about 109 to 1011 cfu of gut microbiota of the genus Bifidobacterium to pre-condition the subject's immune system to antitumor responses; and
administering to the subject an effective amount of oncolytic ORF virus that selectively targets tumor cells;
wherein the pre-condition created by the gut microbiota augments the anticancer activity of the oncolytic ORF virus.
29. A kit for the treatment and prevention of cancer, comprising:
a pharmaceutical composition comprising gut microbiota that pre-condition a subject's immune system to antitumor responses;
a pharmaceutical composition comprising an oncolytic virus having anticancer activity and that selectively targets tumor cells; and
instructions for sequentially administering the gut microbiota and oncolytic virus;
wherein the gut microbiota augments the anticancer activity of the oncolytic virus.
30. A kit according to claim 29 , wherein the cancer is a type of cancer having a high degree of de novo mutations.
31. A kit according to claim 29 , wherein the cancer is melanoma, lung cancer, kidney cancer, glioma, triple negative breast cancer, or renal cancer.
32. A kit according to claim 29 , wherein the gut microbiota comprises Bifidobacterium.
33. A method of treating cancer comprising:
(A) orally administering to a human subject an effective amount of commensal gut microbiota of the genus Bifidobacterium in an effective amount of about 109 to 1011 cfu; and
(B) 1 week to 2 months after step (A), administering to the subject oncolytic POV-601 virus, which has anticancer activity and which selectively targets tumor cells, in an effective amount of about 105 to 1010 pfu;
wherein the gut microbiota pre-conditions the subject's immune system to antitumor responses and augments the anticancer activity of the oncolytic virus.
34. The method according to claim 33 , wherein the cancer is melanoma.
35. The method according to claim 33 , wherein the cancer is lung cancer.
36. A method of treating cancer comprising:
(A) orally administering to a human subject an effective amount of commensal gut microbiota of the genus Bifidobacterium in an effective amount of about 109 to 1011 cfu; and
(B) 1 week to 2 months after step (A), administering to the subject oncolytic POV-801 virus, which has anticancer activity and which selectively targets tumor cells, in an effective amount of about 105 to 1010 pfu;
wherein the gut microbiota pre-conditions the subject's immune system to antitumor responses and augments the anticancer activity of the oncolytic virus.
37. The method according to claim 36 , wherein the cancer is melanoma.
38. The method according to claim 36 , wherein the cancer is lung cancer.
39. The method of claim 22 , wherein the Bifidobacterium is PGM-001.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/660,051 US20220331385A1 (en) | 2016-03-28 | 2022-04-21 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662390395P | 2016-03-28 | 2016-03-28 | |
PCT/US2017/024471 WO2017172713A1 (en) | 2016-03-28 | 2017-03-28 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
US201815744295A | 2018-01-12 | 2018-01-12 | |
US17/660,051 US20220331385A1 (en) | 2016-03-28 | 2022-04-21 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/024471 Continuation WO2017172713A1 (en) | 2016-03-28 | 2017-03-28 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
US15/744,295 Continuation US11433108B2 (en) | 2016-03-28 | 2017-03-28 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220331385A1 true US20220331385A1 (en) | 2022-10-20 |
Family
ID=59965127
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/744,295 Active 2037-12-12 US11433108B2 (en) | 2016-03-28 | 2017-03-28 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
US17/660,051 Abandoned US20220331385A1 (en) | 2016-03-28 | 2022-04-21 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/744,295 Active 2037-12-12 US11433108B2 (en) | 2016-03-28 | 2017-03-28 | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms |
Country Status (7)
Country | Link |
---|---|
US (2) | US11433108B2 (en) |
EP (1) | EP3436065B1 (en) |
JP (1) | JP7040701B2 (en) |
CN (1) | CN108770344B (en) |
AU (1) | AU2017241684B2 (en) |
CA (1) | CA3019546C (en) |
WO (1) | WO2017172713A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112703005A (en) * | 2018-07-17 | 2021-04-23 | 费灵有限公司 | Combination therapy comprising Microbiota Restoration Therapy (MRT) compositions |
US10840943B1 (en) * | 2019-10-15 | 2020-11-17 | EMC IP Holding Company LLC | System and method of data compression between backup server and storage |
EP4206327A1 (en) * | 2020-08-13 | 2023-07-05 | Suzhou Prajna Biotech Co., Ltd. | Mutant ovis spp. infectious pustular dermatitis virus and use thereof |
WO2023120345A1 (en) * | 2021-12-23 | 2023-06-29 | 株式会社メタジェン | Information provision system |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6011686B2 (en) * | 1977-02-26 | 1985-03-27 | 善蔵 田村 | Novel anti-tumor agent |
JP2796635B2 (en) * | 1989-10-04 | 1998-09-10 | 雪印乳業株式会社 | Immune enhancer |
CN100562570C (en) | 2003-06-18 | 2009-11-25 | 吉恩勒克斯公司 | Vaccinia virus recombinant and other microorganism of modifying, and use |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
EP2408473B1 (en) * | 2009-03-16 | 2016-03-16 | McMaster University | Vaccination methods |
WO2012122649A1 (en) * | 2011-03-15 | 2012-09-20 | Ottawa Hospital Research Institute | Recombinant orf virus |
EP2764119A2 (en) | 2011-10-05 | 2014-08-13 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
WO2013158265A1 (en) * | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
US20140271549A1 (en) | 2013-03-15 | 2014-09-18 | Aladar A. Szalay | Use of Antibiotics to Enhance Treatment With Therapeutic Viruses |
US9717618B2 (en) * | 2014-08-28 | 2017-08-01 | Elwha Llc | Gastrointestinal device with associated commensal microbes |
-
2017
- 2017-03-28 EP EP17776429.7A patent/EP3436065B1/en active Active
- 2017-03-28 US US15/744,295 patent/US11433108B2/en active Active
- 2017-03-28 CN CN201780003466.9A patent/CN108770344B/en active Active
- 2017-03-28 CA CA3019546A patent/CA3019546C/en active Active
- 2017-03-28 JP JP2019503388A patent/JP7040701B2/en active Active
- 2017-03-28 AU AU2017241684A patent/AU2017241684B2/en active Active
- 2017-03-28 WO PCT/US2017/024471 patent/WO2017172713A1/en active Application Filing
-
2022
- 2022-04-21 US US17/660,051 patent/US20220331385A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN108770344B (en) | 2024-01-05 |
JP7040701B2 (en) | 2022-03-23 |
EP3436065A4 (en) | 2019-12-04 |
JP2019515948A (en) | 2019-06-13 |
EP3436065A1 (en) | 2019-02-06 |
CA3019546A1 (en) | 2017-10-05 |
US11433108B2 (en) | 2022-09-06 |
CN108770344A (en) | 2018-11-06 |
EP3436065B1 (en) | 2022-04-13 |
CA3019546C (en) | 2023-05-23 |
AU2017241684B2 (en) | 2020-05-21 |
AU2017241684A1 (en) | 2018-10-11 |
WO2017172713A1 (en) | 2017-10-05 |
US20190000899A1 (en) | 2019-01-03 |
WO2017172713A8 (en) | 2017-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220331385A1 (en) | Anti-cancer oncolytic virus combination therapies and elite responder selection platforms | |
US11723935B2 (en) | Methods and compositions for treating and diagnosing pancreatic cancers | |
WO2022222591A1 (en) | Lactobacillus paracasei strain for enhancing therapeutic effect of immune checkpoint inhibitor and use thereof | |
US20230346850A1 (en) | Therapeutic Bacterial Composition | |
Schreiber et al. | Impact of TCR diversity on the development of transplanted or chemically induced tumors | |
KR20230050401A (en) | Application of bacteria in the manufacture of synergists of immune checkpoint inhibitors | |
US20220378855A1 (en) | Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same | |
CN113905749A (en) | Methods and compositions for treating immune checkpoint inhibitor-related colitis | |
Liu et al. | Commensal bacterial hybrid nanovesicles improve immune checkpoint therapy in pancreatic cancer through immune and metabolic reprogramming | |
CN116731894A (en) | Megasphaerella strain and application thereof | |
WO2020243419A1 (en) | Use of poxvirus with autologous induced pluripotent stem cells for vaccination and disease therapy | |
Ruan et al. | CD4+ CD8αα+ T cells in the gastric epithelium mediate chronic inflammation induced by Helicobacter felis | |
EP4046643A1 (en) | A method of treating or preventing colorectal cancer | |
Liu et al. | Gut microbiota deficiency ameliorates multiple myeloma and myeloma-related bone disease by Th17 cells in mice models | |
US20200085886A1 (en) | Methods and compositions for reducing listeria monocytogenes infection or colonization | |
Poore | Comprehensive characterization of the cancer microbiome and its immuno-oncology interface | |
Umer | Improving the efficacy of oncolytic vaccinia virus-mediated breast cancer immunotherapy | |
Orgiano | ANALYSIS AND EVALUATION OF CLINICAL AND PREDICTIVE BIOMARKERS OF RESPONSE TO IMMUNOTHERAPY IN THE ONCOLOGICAL FIELD | |
AuYeung | Immunological effects of oncolytic virotherapy in the context of a preclinical model of melanoma | |
Liu | Genomic and metagenomic studies of the gut and skin microbiome with probiotic applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |